var title_f19_1_19472="Resisted thumb abduction";
var content_f19_1_19472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Resisted thumb abduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 201px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADJAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0aI+uTzx71K21Oc9fxpgABHzDH8jSsxJ6j3rxWj29xkgDEDgn1qrJHk9Oec1ZXupz07UCPJJDFhScR7FGSJjkcGqM0RUZXOfcVtNHjv8AmMVBLCz9uazatqiuYw5IxLjLYbPUDrUe5o8qwGBV+W38tsjGD3FQTxA9evsOal7jfdFV1Drxx7VWaMHIIGPSr4U8bgAT0x3o+zJ1c8c8UrvoHMjndW0sTjfA4Rx6cVycyXMEhRyxOOuK76+/dgr2xnjmudlDCZXaPI7juPpX0uVZvOl7mJd10Z5GNy6M1z0lqYqzXCqGAJOcA4xUyT3BOTFyTzWp5ayHKgFR0FJIRn7hx1Oa+nhVhNc0NUeHUg46S0ZQWGZ2wcZJ4yadDbSMoEh4B7VeLDDcHPGOKQMrHhXJxz6U+bsKyeqIpLYHG8fuwfzpUsoWYM2VVe2eCPpUs2cptwSDyPWpAgPy5+bHGaXM0HKkN8hW3Fl2kY4z1qAxMZAxGFNWl2g4Z8nOMjoDTVUlRyAMcDHNLUem1xqRsSzMSVHpQoOTvwfp/hT1jAPL7sHp2pAsYYkfMRxk8UD2Vg3YIwM45YUu/AY45zjOOgoYAk5OQp5z2NCbmTlvlHrS0QW1sRmYmb5VXbn6UrykjdgcD6c/1qVAGkOep5pZQqx7MjI6kU+dCab3K4G5CxU4z2PanxIWGVTJPH4+9OJ/dgZH/wBamxgqfkcYHB4p8yBJ9CRohkbVJGe5qKaBgSU+U9SM5zUgGcYJLHjJ9KJCy8Aj2x3qeYpR1uyNIjzl2A6fU01omYgl12DjIqRGYqCTyPToKaGYMdqoSeuego59Bcths0ecfvVUL0wKVUVSVEgI6hiOtOT52+UbSe9MwSQOCewFHPfQIxQiIu5i3Iz0FC42fOOe2O1AXG7jn1zSl1C424Iocxune7RKEVoh91mPIx0qFo0/iHToOvNLIQF6bR0wKaNpX72D2Bpc7Hy30YGPPJ+Y9TmlkwAMcHodv+NMVTtBGDRJjHAwe9HOxcmgp2E/cAX0FJKzcrj5R3pp4wAuR60FgWw2OnHNL2lw5bC5AjK5yB0I60xZGCALgLnJzS/w5XAUDmmEgnLdOxo5x8nUlifdjI49R2pOo2Fh/wDWqEMBgg8emO9LuyMqefTHajmEokhbAwScZ4OKYGXDFW3PngY4FODZ6jimPx7HHUUudlSV+gx3cN1OO5xT2P8AEeG96YzNhhx6detBZmGVHzY4z2p81xOPYkJJxkk0gO0kk5OKTeAdp5JpCRj5VI49etFxJPcDJlTu4x6c0CVcAJ+OaFYbTwC3TFMKqr5YfWgFFjpCDxx7+lCvwUGFU/zpspGVAUAdaSRCrk7Qy+9Ibj0GmTPBAAWpQVIPBxjnNR/KXPBzjkCgOACMbT6+tAW7i52/KOFPT0pMEkAE9Ov+FEmBzgkgZ60ZBPykg46dqL32BJdRNuwjucde9MPIzzzxjripcbunHvTCNmODk88dKTdhqKW4ZBULg5HO40VGwDglmOfainuS03ue6xodxyW55PFPeMbRyPQ8UIcsAOD0qwNhXAGeOlfA3PrSmUGSuBkdqkjjbILL175xU6opJPpzUoXd0z9CaV77A5WKhiHb73rmmlMAg8EVZfgkDIP8qrTZKnqMn86tU77kX7FW4RVyeCazHUE4Ayc1oSg7j68YJ9feojATyMDHAp8sVqVF9zKuVK8DoetRKxZQrnLY44rVkjBGHB3D1/rVSWLkhgdvXjsKhqxSKLxq3I5OMday7u0OCRyvuK3doC4C8/yoa3DdAST3Bxms3c0SOJuYGjffCSG6nng1f0We0mmMF3GiFj16ZrVvdMLqdnJGa5bUrV4dxZWVx39DWtOvUScISaM6lGEnzSjc76PRbTGViUj1PNSLpcAIIijH4dKwPBfiJpn/ALP1A/v1XKuf4x/jXbmIMQVPIriq18TGXLOb+81jCml7sUZJ06Hj92n5VXm0q3bO6AHHoK3gg4BHNOEQIHGalYrER1U394OnTa1ijmBolq5z5W32BxxR/wAI/blt6hvpmukWFeTjNKYxtwBjjNbLMcYlpUZm8Jh39hHNf8I5AzEgP+FRP4ajJO12AFdbHERgEUrQksDVrNsatqjM5YOg94nDyeHHVSEkyPRhVdtEu4QSqo5z69a7/wAkYPHXmgW6nqOfpXTDPsZD4rMwlllB7XPNJbC7jkB8ljgdfSoHimjDM0LbvXGa9QNkhXhQaiewiZcbQO2K7YcSVPt0zCWUw+zI8xIbA3Lgnr7UiDMfHPPFeg3ei28wAaNSPpWLf+HAI28liD1r0aGf4aq7T905KuV1Y6w1OYwcbmxzxSuRs+fnA+8K0I9BvGzvZSM8e1Ml0a8RCHQsR1wc5r0Vj8NJ2U0cn1SulrFlBGGw4BA9TUeNuNign+fvViS3uFcCWF09gM4qOUEYAXn69a6oyUtnczasnFojdmLbegHIpdxy27n2HenY3EA8HGDTHjwBkYGc5HenewotEew4BJxnoTSgHoTznrSytjgZxmgHPfvSvcHFdQkGFxuBI9e9ChSx3H2NAUtkkjAoyGO1ewz6Glrsh2QisFJwPl9BTSdq/KOTxjvUgjY5KjoetK8bEB1z69OgosNtbETJxkEqPemMCZuFBFWiuFHIOD+QoEWZRh/lx3oS7hzEDBtpACimqrBQCA2OSferRThuM+uP50OoQrjPI5Yfyo5SborOvUlsY6Co1G04/H61a2qSSSCM4B6GmnczAMo5PA6ZqlHQOdIidct978fWohHuOc8dxU7hRJhRkehp4Xy1yVwT2xUNW6jcisVUscr06c0Ic7iBipnC/KCDj+dN8slwHGABkU+XuLyIWAAIzg96FRt33uB2qwyg4Crlu2aZMCCNpGQMe1GuwO1lYgOQSWwQeho9zz9ae3zKS68elNBwTwD6DNGo2xjFXXaCcg44pCHY4bIx0GaXqx2NyecU7lThjjPrzQJIbtyeOCaQkb8Dr/dFShgvGAMDHFMO3IK/nRcJPSwgThs5JPpTSE8sAAj196fwSWUleOAD0pCNrFTnJ547U0wtfUaCQM8HPGaUE5IYnFOHHcdec96Mb2Pt2oYRVyILk+g/lRSnljwA3oP50Ut+olG+7PelQA7l+96UHJBIx/WmghiBzVhIw3Ixx7V8HufVbbgoCjd1buKRpV247kdhzTJnwSBjPemAAn5jn61agkS9dRrOSeR16U1uRyATnvTwyjsMetGzOQRgnnmq2KSKZAZiSCMCjCK+Mdall+XBxjt7VX+Yghfrg/0otcY6RAVGOoPWqzJ1UdfftU65zkHJI5JpNoOe3qc1LQFJ4gTlhn1wMYpqKQcY/E9D9asyxkHuMdP8KjTjhhx6dKlxuaxZIiIxw6gE8f5NUtV0uG4Q5QHHYHkVoKeithkz+H40rpxtA2+vqP8AGs3C403Y8x1jSpbK8Wa3BVoyGUj+tdvpGpNPZRN5ql8fMAag1aEOGHG3rn1rAkjfTZBcQHcmfnRen4VNSm6kUuqGmjuY73cfnBBHeraXSsowetYWm3EV5bpJC24EcjPIq+jJzuA/xri1joxc11c0Q4YZqRDntxmqAB/5ZsRTw90vQqw9xindMfMX0GWyOKfJHuI5xWcNQCkCWMqfXqKtxXscg+8DVXjoGvQkVCpIbn0qUAHp2phkQgYYfhSZ7hvzp8pLuyVAT0prRgseOaVHyPp3p28BhwaTViVe5HJDxgdqrOnABAIPpV53U9jgfrSZjA5A5rNl3sZggVZDlRg549KSSJGXt+NXJmQEHjGahn24DDpUNFxZQmsY3XJUY9DWNe6PCzAqgB9Rxiug87bnAPTvQTuUjA59q6KOIrUdacmhTpwnpONzgrnTGjYtHyBnIPUVlzK25QFIPcGvRZbNZDkfKaz7exCTMGVT+Fe5huIJwjy1o3Z5tbKqc3em7HFC2uGdcQu2e2OlWDp92eVhfYOfu16bYWe9AxCrx0q6LePuuR9K0fEc38NL8TP+yILeZ5EsE4YqY5PTG3ikW1kLHMT7z3I/SvWJLSI9Fwe3FZ9zZKwbah561ceI5fap/iS8ni/hmecKjg4IbPTFWIrG4cYEL9eo6V15tIo4+UGVPHFadlDG8QJGKKvEcvsU/vLhkyWs5nADR7w5HkNj/aNSrodzvViqrgfWvQRaKT9aZJa54Fc8uIcU9ootZVQ2bZ55Jpc0bfd6/lVqHR5WC72Ix175rrLu3QJgoeKS3t1ZF29O1RUz3F1FaKSNIZXh4u7uznY9BTnd3H86sDRII8FkHQDB710n2UL94npjimm3XAJOQOlc08di6nxTZ0Qw2Gh8MEYS2UYdf3K8dPlqSSzi2kuFwfatyONAMkAZ9apXCxEsa571Hq27nUuS1raHL6jYICTGACPSsBkeCYpu+cj8K7O72JkOcj+VcrqrRmTrgE5FfR5Rjqjl7Gq7nkZng4KDq01YqMcAj8OKXyz5e87cE/54qRiBHkE4HfFRhgQqscN1DetfRnz0b31EkiJGFHPpUTwkLtA6mrBYlMFuM007N29mORwKkaWt5FUIMMAvbik8rK5OcYwec1YwN/XJPTiibAYKGLOepA4osx36lbZtBwMknv2oIXO3BJ7mrIVQhZiemetQttwOGBB/Op3B7EO3BGCD6ZprMMsejelTuq7Qykg8g5FRkKT0+YfrTHay0GSMuDjgnFPJUDCkcDJo+XOcA44zUcRHzEjp6elHQd0hQfmzxj1opVwV3SdDyKKWnUnQ9yjwrcg4/WpVcsx2ZA5+aoio6cdcgk01n+fAywxn2r4pI+pbuPx0A5ye3ORS7huG4cH3zUZcDk44Bz7Uo/hJ6Z/Ghb6iSJBxz0zxzzmnEMMds84qMPh0HJINSO5ycN1oSAhlBK8qPbNRNGoOQc89feny84X8c1GWyCCMYOBTAY4BBbqOv0qNSN5Azt9MU9yD8vU9CB603eF+8MA0WKuEmWQ9PT3/AP1VX5Z16AjvmrIkG45OcHgmq7sBIegH86LMakOXdjrgnjOMg0rAFR6jgH0NNLsDx16c0m5SMYxjrz+lLl2HzGTqaEKWAAGcsvoayHhMoAyADjK/1z6V0d7Esibec44PtWS8Z42joRj2pNMtSuc/DNNo94biLLwNxIgHT3HvXd2bwXtsk0EgcMAfl5rk7+3YLtJA9TVXwtq6aNrJtZ5NlrcH5Nx4V/TPbP8AOsp0lUV1uLVHeohVvarKqx6ng/jU8kYmRWAIFRCEr1J9q4ZU2BG9qW5wcVQubBl5jOCPQ4rYHux+lIIwxIzge9S49Bow4bmeFtrnI+laMV+rcMBmm3dqD8wINVBFjPHzenrUyh2KbNeO4VhlfwqeKUMwVuGx1NYyA7ht49anXc4OxwWz0PWs7NaME09zZO0EYYGhkVsEH5vrVC3uduFnQgjv61ZjnifrjNUrMVhzwpIMciq3lYyuckVfb/YYH6VC37p9zDOaVu5UZIzjAcnJ+hpViZcdxWntVsMMc+1NZEB96cY20G5ozZtwXJUY9qo3ABGTwa2mTPDCoPKidyXwPTNNxtqJNWKul6gQwhlyT2bHWtlZcsNuCD+lYt1Zxk5RuaiguZ7VsNmRR1zwa3p4i3uyRLhfVHROyquGxUbFCnBBrKN+JvutjA6d6aJWGGGcV1pRauZWewt7CTINvQ9TUlmvlqQ2eKbJMWxng/zoa5URgbgSetS1BblqUmrFlp48dee1QtdgH5TxVCSQv9wEnGar+Y+7jB9alOHcdmlsaDXCuD69qbazLEnv061kyzSoOEJJ7ZqleXzwrlkZVHJOa0XK9ha7HSPfL6cDrVW41ILgdu+K4e78SJECQ44PrXOaj43UZEJLsOoFdFKhUqO0YilUp01eTsemz6usancwJ9PSsm78QwRqfnVcdTnFeU3niG+uyxRih7DHNZm2ecl5rh2OeATXrUckryV5aHDPNqEPh1PR7zxNFM2I3ByerVh3morJKSzhgDng1gW1kSRnLHvz196047fYo2nB+lerhMmjh5qbldo87EZvKtBxjG1zo7FzLEGAyxGcdqVFw8jdSOoHaq2lCRkKhiF61eVG3lCWPfjpXoNWZ5t9BindgEZx2zQMM+SAPrmpE+Qtnk46AUMGaNWG7GcYpMaKxRlnBVQBnnFTjcwcqoBHGcUhDjDMGB64z0pjuzOAhwOuQaXKNtAqMFI7Z5BHApXRUTjoemTTVXcT8wKjpzRMq46MQR37UmtSk+bYiBcnLEM2OBSMNxy21fp1ojRVyASB3xTipVwFYt+FGiJWxGUHl4AwPUHvTWDBFOAD35qx5ZwcucZ44qOSMEgMWPHTFILtkPycMQSx5GKKeqop28lielFBSPa2IYE5+lQc5wxGD3p0mAxOcKcYAHembwuMkgA457mvh9j6tIlO1Ac8gHAA705SA3JBOeh6VWabcNox+J4pY5lxycEZA9qEhdNS5lRlj/OlkY4Pr0HqKpG5QR4A+bOD71G1xzjcMenetFG5JakkVAc9MVAkmZeDkBSeKrvLhCrHd7e9NgO6NmVsA/KfoKqwh7EA7lOPamCQMSF5xyT6VFLIBIE656k0IQYSPuhucj+6P/r07D21HBiwGTjuP8adggkN6ZPtRGvz5wAOgz6/3aeRgZI4B6+9Kw0xm19uB8x6c0q4yob04oY7VOOSOmKkRSx5xzxn39qBqw2VAcDoepPaqpiUsOOB0x61an+cMgO09CfSoR+6G0csB940raahbTQxtRj2rgY3fyrktTsd0mGHJHzN/hXb3MZkLZ4A5LHrWPqFoQCzDK+mOlZ25dUaLsWfB/ixoMWGsuzoPljumHX2f/4rv3r0RFWWMMvKnmvJntAYSc84/SrWi6xqekIqQSGa37QyHIX/AHT2/lXNOC3J5WldHo8sBB5Y+1IU28Vm6T4ksNQcRyuYbj/nnJwT9D0P4VvRoGGRjP1rJx00Dma3M9kDDgGqc8JU5FbLJjmoZYlZTn6ik4W1K5uplRxrKCw4YdvWrCwLNHkfKRxkGqx/cXC55B7irLyCFxKM7W4I9/WlKnfVj5hu54PlmBdOx9KkS2gny8Egz6A1fRUnjB4NUbq0aM74cq3UEVzumP0Fjt5EOCzBv50k7ToCG5A7mo4790YLdLgj+PtWiGjuUxkVPs1bcObuZ8V00XVcr3qf7Qkoyp59D2p8tuvIFUZImjbKgGps1oWuUupKQQKnRo2ADYye1ZkNwOkpxzwTV1Io3UEMCTxSXNfuJxQ6S3jk+6BVOa0I+4xIq0YmQkBhimhX/hOfY1qmnuhWsYlxH2kXafUVesod8YwCccYPFJeMdpDDmoNOvAk3lSHg42n09quCi9Btu1yzc2h3JnOAe1XINPXAO2rqlHVSVDDP51YUg/dGAKp0U3qT7RpFX7Mir8o5qF7RCM7QK0S4AxgVFK2eBjFX7FWsjNVJbmTPYpjhazL3T/MhdNuQw79K6bKtHiqssYOSOg6Unh0ndFRqs8/fwpp9yWFzaxN785qG18FaOsrA2KEdjk5rr5VZZWCAZbrU8MZCKWxnHpWkaleHwSa9GVJUp/HFM5RfBOhhiRYID3OTxRJ4M0UAeXandnP3jXY7BjJqNkxk9KbxWLX/AC8f3k+woS+wvuOLfwZpiY2xOvoAx4qrN4PtAQUMqn+8Tn9K7ry9z8j8TTHgDKK0hmWOi9KjJeDwz3gjgU0IwMypKcN2NWxomdpDOxHTFdLdW6ouR19KWKBlwz5zjrXQ82xsvtE/2fhN+U5d9EZCPmbnnr0p8eis/UnHua6aSMAknPHqKXKGNcjn2FL+0sZL7bLWBwq2gjnE0KEKC65wKcNJgzgqAMdTWyWK52gn61FJLGScjHPWoeMxTd+dmqwlBbQX3GBd6UikGIlQOoArFuYpI2OVAHqT1rs25Q8ADPFYmqR5U4OAe+M16mBzSrGShWd0cGMy2nKLlSVmjn33R5cKC3YeoqQcgDb8/tTZN2WU5ODxT8EcHr1NfTvXU+bVuo1nGcBSBnPApgJBOFIHvUjDB+UjHTGe9JJh5FAwCOvvS62K1uRFVOcZUk9cUU6Tg7FIwT19KKqyIbtoz1uZ8ZyMYGcCq/mAj5efT8KdcAHdjpzmq3IO4Z3Hpz+FfE6H172Hs+ASVLcY6dTVV7gBdxJiIAHzcVYLFRjPLcDHesfUctG6FeV5Vh1P500tSG9CzJebIywww6hgevtUEeqLvLHO7HqOTnpWFGzybgXAdQGIPrVRGIu2y2MDoT0q1HUNDrHvgV3Ky7ido+pq1HKBAoXLN1Hue5xXHW92JpVbdlEyMDoT65rXg1EIeDncMeoFacjFZ9DTWXc5UsVI5LdvrVlHBCblyxA8tMc47E+1ZUM6yfKiF0Jyc9296uwPKkqu4z2LsecemKbihdTZWIeXlhnbgn60kCtICo4UDk9h/wDXqKOV2AAwoAzz/M1ZWSNEAD8E5OOrGp5SU2QS9MKNka9PX6fWm5bZjGDjIOegpLmZTnkKOoUGqa3O/csZznp6k+9DiVF3Vi27ZZNhOW5PqPUmgoZWJUHZ2z396kgj2qTJht3UZwPpUjtucs/J6cDAxSasXsVGjBB9M8e9VLqJWQg8Drk1oMwbAGAKruqljzwOfrWbiCZkSQj5kVTgenp60Q2eX5HPIxWrFGWDPgljwM9MUJASwzyf5VlONxqVjKubBCMMoPcH0/wptjrmoaMfLcG6t+ys3zKPY/41uAMYyGUZINULm0Drk4JrHkcSr33N7TdftdQQeQzB+8bcMv1/+tV6SVyuFHzd685ubAKehyemOCKvaVrN5pRMbgzx4yEcn8wf6Vm5PoCSR0d65yRImKmt5TPbFWALDg/41iJ4mtrwkS27wv3YHctXtPlUtuhYGN+pBzVJq2o1Y1dFufneF/vqcDNbEvK8iueEbxXSSrgq55Irot+6IEDtU+zvsE7J3RRltUYNuFZMvm2UoaLJTPK+ldA+SuRxWYF824YMOB61lOkkJMltLlZgCT1qSaPOSBx7ViTLJZTnb/q2PQ9q0ra685dpx9PWuaUHsaxtbQHt1fJYfSoJreWIZiJX27Vf5DDHSkdhgDd1pKLHvsUVllVf3g/EVLHcbuN3PpRsckjHB60S2SsRjggUag1YfKqunIBzWRdWnzbkBGKuOk0JwHJHTntTUuEZgswwatxuLncdyax1EKQl0dv+12rQa+jDYjOaypbdJkbZ+FMt7R4RgfXrW8KritURKClqjU+1Z+uaVpt3OcfjWVdecIjtJGTUkVpMyKSz/WqliUtUhexfcttLgZJP50/7QoAA71VS0kU85/OnG3IGQWz2IqPrHkHshsZzcOzjK4yMVKXC4xx7VRk8+I5BPHqKpzXE2CWBH9apYmLsrWH7N9DWkn+X+vpUInBYkGsdL47woGT70sl04HArT2kOrGoNaWNRp0AJHB9/Wqz3qnIz+ZqnmZhgY5HWohA+QCfm9Kn2tOOtxqMuxeMgZhu71LLeIAMdOlUPIkIyT+J4pfsO8ZMn5UfWIITgySe7BOB6cGlN5EcbmXB75xVOa2KycE49zVN7Mm43NkgdBngVccRBouNJ2NOa9h25RgR+tVnuIto+YHuRULQFT8oPtmhrcqPlPPQ4pfWL7I0jSb3ZHcXgYMIwSOn/ANeqF2s0ylQNue/vWmYFVQW61IsSbMDqaFVlujRUl1Oag0mQEl3JHQYHSp20Z1H32P071t7djY25HXigvgcsQMdB2rtWaYxbSOSWWYZ68pys1pLEDgZHsaqcMMbeneupuIlZc4w3Y1kTx8k5+uBXu5bmf1h+zqr3jxMfl3sffp7GY5ymDnHQgdqKlZhgljgj1H3qK9uyPI06nqUmQwUr2JJ9MVXYhGXK5Az1q3OudxIwR39Rjmql2vHpk9Op6V8PufX76CS/6vKcsOQPpWbcRRvC24DJB61JJMyRZwxwMAjnPrWa9xNI8o8pyqoF44/GrizJxaMMAxO8e4t5bHLVUS2vLss6R+XEx+8f4h/hVu3jlvLqWJF2kklt3Ye9dbYaQskSrMxIQYx0rdXWo1rucjHZy5VcGTb0xwM1pWOlSvHmdAMHopPFdQtkiMFwMfXAFMdAzExeYd3YEcUtnY002RQggS3yNzDAGAvQ/WraP5qqVyADgH3qzBpu/mRmI7DNW4oohHhiq4PBY0O5m+VamUGkRmUZIPPcmh5XBBLZwOKvX9zGinDjK8/KcVy174lt0JWB/tEg4ATkA+ntVJXehMnpdG2iyyBiADt+8TwB7UtjE8UxLAEvx7KK5VdTvryUK7LBECCIwTz9a6G1uZHjQXBGB2WqfkNLqzcmYZB3F2Heo55VVMnkmqzXEaLtRh7iopp0IBc5Hpms3HsNO+44yn7/APB3FSgh8A8+uKzfMBO75iufu+tSrKOpJGR09aTiU46GouFUZzyMYPpTg2QQDwBVFJ+fnfPOcVZWUFskEcdPWoaFbUssoyR0x6fSohH+7YelO8wYLc5HBzShtzcAYGOKjl0CzKM1vlATgkHk1UurPc0YHUHkVs5XgAZAJqOVAXHBA6E+npXPOFx31OR1DTHhvCIGKFxuUDgE9x9apWcs1lckszRtnOR3+tddrUPypJu5RuT+FYWq2jO9swJJLdQKycGWnc34tdlit0a6gVkx9+Nuc+4Namm+JLGVD58vkY/56KRkfUVySzG3hZJgGUDABGc0kEZKDKbS3IBqU3HVBZtHoQ1HTXUst/bEHoN4FN02a1lkdxcwbc8fvF/xrh1tVZeQD3qGfT0J3tGr+xWk5uWocum52uoXFjM5UXtsWzjAlU/1qPSwhkO1ldemQa4Ge1gUjyYQoPBwOh+lTW4ntirQSyRkcZQ/0rNxuVGLSseneUp5U4FRvBvHHauJt/EuqWZCStDcp/trtP6VsnxNNLCXggi44ZWY5FJU9LhdxZrmExdKY0hA96wE8TXjt89nCR6hjVqLWBKf3lq6A9SpzimqVitd2azPvGGXBrOvItuSB2q7DLFOpaNiQOx4x9abJHuyHziplFgrMyYLowuOcL0Oe1bdk6yRAnP+NY93Zgo5UnpzVvTWyiqr5wAMdDW9FKSsyJLl2NNolZ04+UGrwC4Ciq8ZBwSwwBzSmdADgjFDpxRLlcseWpBzikNplQRjmqxuAvJPFO+3HbgGhQiyLyvoRXFsCfmHSs+6twwGV46VqrKDknn+dIWjkByMH2qXSTLVRo5SexKzbuRnp7U24tSQADkE/ka3LyNQvY496htYBhWJyR1zUujdXNVWKlrp7eUN7HpVpbVQuFXPvV4qAOT8tReagPUVHsRe0ctSr9l2kEj9KPKB9gKsTXSkEbgDis+51GKEYDBn64qlTS3GpNiTxAnkA1QmiCjcAMDkiiXUJJSfKi/Emq7rNKD5suM+gotBGq5i1II1iDEr9arvPbhDjGQKakEQxuYu3oT0qQ2yHjjJqebyLV+pSe43jIjb64pom47rWokSBNu3Pao54EGQwx71Uaj7DlPoUg+8HLc+uaFXJxUE4MLkxnIzyKsCaJYlPHr0ya6qaUlZEurbQhkjK5BJPtWJqb7XPJGeSV61qXFwWUuc8j8K5PV74LLhG5z35rtwdNuvHl7nJjKkfZSUuxM0m45VH5OcmiqEDmYAiTcrDmivtHJLc+NSbPbJscYzk/yqtIu+JcYDemO1SzPyu/OMYqBpUbAyd2OFFfCI+wWhR2YyuAOfwxWLMUiuiHXfx34AP9a6MMpLggEnn6n/ADzWBrimOaNwvDdfc1omS9XYNJEccl3xglg2V7gitiG8ERYdvTP864XUdWbS1kuRDJKMBCqdSc8fhVK2v/EmuECxii0+Ij77je35dK6YttWJ5lFWZ6BcX8MK+ZcyRxRDJJY4H1zXNXvxH0e3nkht3kuGU8G3QuD9D0rk/EPgrZYz3+vX1zfPEpbLyHAPYKPc1j+H9EeJA0UjI/fPOKco23Ep8zsjvH+I7zACy0e9kLfxOQKbLr/iS9iJhs4LYIMku5dsew4BqKxsr1VBjnjdR/ejrbhsr9owN1uQeRlD/jUXsU4PY5iWxudRBF5qNy755C/IoPoVp40iW3wzWyXCAcvbnZJ+XQ10k2g3k0nzTxo3UMFNMGj6jbDcLiO4PrjYfp6U4z6ClTvszEt5FZTHBeEP0aG4Ta3596naXUYUGIo5Fxj5JKsXVvfSbhc2ccy9MZGc1m/2begN9jt5ofZZcAfga0uupHvR3LS6herjzLV4885LA5qaK9JUeaW59RXIa7rd7oLIL2RmZ87VIBJ+uKy0+IcjEh7ZSOmcc1pbS5EqyR6nDdowHb0wakFyoc7mwAM8jivMoPHFuzFGRlyM5z3roNJ1VLx0ZpVKjB2g9KmUNC4VlLQ7O2lMh3DlemP61qRyYIyQcD86zLNkKAd+vAq3DsIypyB1NYuJ03Uty63zLweKfu2RE5yTxntTVjBjAycDnNSxwgDluetZNaC5l3IoZSeozjoauQgOSGPLUIY9p3Yyewqu744HBHIxWckJ+8P1DD2pjcDOOtZgjdlidxnaCCP61aeTfjeRu+tMkdWDqGAPpU8l2CVjHliNxdIoUlVOTirnlkycgALwPSpreP522j5s/e9allToqncT0I7UpU7lvcjhPHQbR6VMwEkR35+tCpsAwADjmpwp2EEfK3OKydOwr2MyS23bjtG4dqdiPgOmD7jvV11G4dCaZHBuOWxjt7UKizRS7jBYxzA46Hv6UxtNUZVhjtxV5JPKUop7de1PUswGT+NNUCZTILexaMHcqyIenYirsMQXqNoHqKh+1eXtIPGKin1Dngj161fsXayIUmWZpfIuE8kjBIDe9X9zn72cEVxet35nj8iPO49xVrR3vY4FKXDso/hc7h+tc9SFkaRjodFOwXO0E5qIW5Yh/TkYqqL9mlSO5QRDP3ieK3IQmBtIIxx71jKnzrRj23KS2pb5cn6VIlqc/MOB0rRCYHtS+XuXA/Os1RsiXMzngwOCRVaUSxHKuT9ea15IGUevpVOeJipyKXI1sCaZRW/mXIKDHtxTItRkYEqhPrzTpUZM/Jx6+tVIQySMMEA9AKrnl1ZSpotC5kuTtJAI61OZZVIAfA7gCswNIs52jk1ZDSsRmpdST6lqjFDpmctxIT+NUXjZifnJA96uMGxnHX2zS+UNuFAPHTpUqMt2UlFFNIFxkMcnpVY26pJyvJ5xWsUZeuM+1VZx15O4enarjGxorDWUhRtOB3prYdQNuT61NHGWUMfSnSg8BcAnoRVxTb0QXRmySeVIu0Ag9fWplmVgB1Ydgae9oAAXIORwaiijEOW3AEnGTWvIkiuaLQ4ZLBefapbmVQmzb0HXvUXOeSajlbAOc/X0q1SvsZydyrcgnI+U47iue1m/XToZGcnaDnj+Vb80i7TjPFcZ4suAyOvOR1wMk124HD+1rxh0Zx4uqqdJz7GXe+JpZ4mFtEwGMEscZrNaWWdN7hV9cGoLdDkfK+Pp1q7HGQikr3r7KhgaOHd4rU+SrYyriNJPQuaXI6kKqpjHcUUW2I5gqjDEdzRWsrX2MNI6XPaGk3ltynjnNQblDfKp6ZBPNRtI3O0hu2BUecOpYEDGAfWvhrH2RahZc5IqhrkKyJu6k8HJ6c1aTO4BHAycnP1pzW+9dzbSfTHTmqWpD3ucRfw7DtbqCa0dCnX5ZUXGBgj0NWtYsN25kweeR2rADvp0vyjEbABsevqKuE+UVlOI74kagGtLW3QfLLKGOD/d5ArP0cJtQYBzyRWV4xuhcy2Eob+Nk6ewOK09IcEKvBJxx61tN63FRtF2Z2dmsbovl4C+h7Vr2I3DA5Gcc9axdNZVix/Ew6Gt2ycCNeMqehqdGbeRoxwExHIAGaSS3CEbsnPercMqHBYkhefrSTzqcfLyOTjpRZIz5zFuYER24/OsrUp47eFjkcDOfWtLVJQFc9B+lef+I78y/Ihyg59Dj0pxi5MmctLnA+IpbfVdVka7ZjsOFx0Aqg2kW0eG37oT1cfw1n6rpdwL6W7tpCgJLHJ46+lQrqN5YgfaIsxjPzJyp+orvqYSpDVo8pYmE20bFx4ZaSMS2rrIMcDFYwN/pU+Y2khkB/A/hW/oWvIjhYpP3bfwE9D6V1vkadrNviSNRNjG4cGuT3oHTFcy0Zl+G/iCYBHDqaFB/wA9ByP/AK1ekaZrVtdRh4ZkbcOgOR+FeUav4PkhIa2YbSMrnv8ASsGG21LTJcwvLCRydhyPyp80ZFxnOOjPpGO9zGFIwPr0q1DL8pYHn3rwbTfGWo2o23iFwD1U4/Q101l4/tnAEkjRk/3xxQ6Sexoqump6o0sRYcnPpTSVPzbuOma4KLxVZzDJukUDnOetSz+LIFi2pcJt68HmplRd9DeNWPc6q5kSIlmIHuaqxMzq0gYhei8f0rkz4iiu3JZgYwOMn71aUGtRMkYVwFHFT7GSNFWTOhtrhgGUkf8AAauQHeeoBrmU1K3JB3gY4q3FrkEIA3Bt3cEZo9k2EprodTEFCZYjFMeYFSigc9/6VzUviCEjLMPpmqUviS2jHzyKPUZ5qfYsz54rqdFNJ5Z+8c+lEc+8A5KjGTXEzeKI5ZMIfk67j0NOj14uoH8PoPer9krajVRNnYy3yKccEnmkXURzhuO4HX/61ctFeXExxb20zv0wENaVlpOqXTDfGsCgZLSHp+ApKCRTqR6l65vxkliFX0qG2tru/YNCh2H+NugrV07w/DHMskzGaQHjd2+grrLFI4V+ZVA6VEmnsL2nKvdOMGgtHIC+WfHUitvT7AJDtbGF9K2J57bOJF6Ht2qJ9Q0+IY6AjrmueVK6NY1ZSVrGfLaxdMDP+1zVIefZvm1OV/uE5U1fkvbCZgqXCAnpk0IFcEoysMdQetc86TWpsrNalrTr9LtMY2yD7yHqP/re9aCkjP5CuZuI8SCWI7JlOQw6j/H6VpafqH2lORiVeHTPf29qI+aMJwa2NcHIwajcblPTr0qH7R0JA+maQyMRxxT5UZcrRDPHlSMDArPkTbKmQM57Vp4y3zZLVRuQv2hACQQal01c3hroLFbBp923jFPMe3jAwKt/dRWBwaqytyeQc1n7IalcRUBzlcj2p6w4QkjrUPmDBIcDHake7wuFPHTFX7PTUV29hXjXqSCR2qrP/q2K/eA/OmyzAuDnC0jkeWcMMdaHSRadtxlsC8JJ+8Bk1KsLMxznGKjhuIktz843H1qlJqHUK3I6Voqa2Q+d62LpiYzEBhjHOabdKm0DKk+1ZE+okbgDlfc1UOqZUrvA9T6VrGldhKTWrNFnG04PtnvVG4vdnUj6Csa+121tU/fSqCeMA8muYvvEhmkIgAXPc9a7aGAq1naETlxGOpUfjZ0Wq6wsEZ+fDAEgd64q6vZLtyW+WMnOCOSaruz3Mu+aQOx9jnFTJF+8DF4xx2NfSYLLoYVc0tZfkfOY7MHimox0j+ZZtYmdeV5XkccVZWLkiRc98jjBpLDeyg/dOdpJ6e1ascRZCAcHOSOua7ZOxwJ8yKcEYIEaqcdziiryxZlIUEL6Yx+NFRd9C4xlbQ9CIwAQPTOO1IQGYDcwx82PSpFQn5iMZ6gj9aSUOB9z5jx1FfEJPY+vvcdEqttyGyBn8KvRJlVPXPBqrEgIxu6YHXpVqH5lB7jApbC3ItShBjO4AHv7jGK53ULFHikVgMc49a6948xtuHJGMYrHuIh82dvpnriixnF9DzDUtJEvD/KynKtnpUenGSzlMcvBH3fcV2+oWIyOOcccdaxry1QgZXH9KcZW0NbdUaFhMXTcuSCOD6V0ljIGi+ZhkgfhXGWLssjJkhuoPbFdRpMoERDDnOc1qndDv7pvxbgmNwx/OmzSxrGWZsDPPPNRtOph+U4yMZFZdzIEDbm5xnBqvQxvdXMnW71irLnAz0FcjrC+TaZ6u56DnjvXQTkSzsQOM8VzPiLe86xowBHTuCa68FSc68Y+Zz4yo6dGTOfkjG6PbFk4zjrkUrWKFjFMrFc85TOPf/8AXU8YZ1CsAAG+U4/TNOAk3NskZmB+bY3Pp3r66yeh8tzdkczq3hVpGEuk7UmBOUzjn2qjp+vXGnXX2e/DxOhwGJ6Gu4aYjAlO1jkYPOMe4rP1W0t9UiKTxRbmH+tA5B/xrhxOXwq3lHRnTQxc6bV9UdHo+u2+oWKwrIuCAcZyM+o9KnurUYDJww4PrivJ5dNv9ElE9kzSxZyduePwrpdD8cLKUguhtkAxk8HP9a+dxGDqUXse3RxVOqrs6oWdrcEie3jZxwSRz9aSPwxp88hzGyLnAIPT8Klg1G2uxuVlSQfgTWpDdQsiKwGQfvqcHH0/rXLqjstFmZH4M01wMSOWH6fhU7eA9KZco0qnpnPGa10mRv8AVOrheeuCBU0N/GxABJb6cn8KnnkPkTObHgOyJI8yaKQeh4o/4QmOIbVurjp/e7V0MmqpG2yRuQTiiPV7eZDGJEBz3ODT5pk8qWxzkHhqOMkS3k4x054/+vW3ZeF7CUJ++mdl6/vMCp2vIRwxBPr61GrRNLvibk8gg96Tk2g5V0NBPCumr8zRyEdSDIcGtSz0rTbWFjb2sIJ77QSfxrMtdQMLASk4A6sc5qe6vw9qwhdevH0oUmgUW9zVFpaKm1YIh77BUgihjCBY0HzAkBRWVDfM0XqeO9TNeYUjq4OcA1DkzSFNM3nkSMcYx3p8UqsuVPsDWHLfmSE7B8xGBgU22u5HwZGC44PHSk2w9mkjfW4CsT3FNm1TAxu6VhT3pGQr7s9s4rNvbtgQd4yfyqeZrUuCUnqb5na9dhnEYPr3q5ZLa5CvChI6E81y9jfrAqLuBJ9+9WnvQJN6sQGHXP6V0xjaCZMpNysjs0t7CQglEB/3cVNFpdm75QRZz3OK5GPUunzke3rVtLzPBbnrWUoJ7o1Slbc6LUdL+zRBlU7SPlJ5z+NcpdSm0uEnjGOzDpxWjZ6lKS0Ekh8p/wCEnofWsrW12pKGPGOvrWLpq+hUJPWEy+L1t3XaeuKvQXi7gCeozXDQ6ukSxK5HAwAakn1pFXKN1/WnyMz9pd2O9+2LxyKp3dypyerDuK5WDUJCm51x3UZ5qJ9TfIy2O31o5GOMkdeb0Mo5ODUb3S5OCOfWuOm1jYPmaqU/iKCIMZJEUnpk0/ZOXQtyju2do068nd05OahN8iEljk9q82v/ABoN2IDvB4Bxx+dY8+u6pMSEkRF9etdtHLK9ZX5dDkq5jQp3TlqeoXWqBTwwGKzrvXo40w0ygfXrXmMkl9dH99dXBx1KHGfwFV2sIi+JSXPBHmMfzr0IZDUfxNHHPO6aXuxud+/iqyi5Nyg54+aqFz4wgJ/cB5j28tSf1rlV06BeFgTJ7ADj8asiEoFVQqgDoT0966YZHBaykctTOqj+GJbuPEl7O3+jwqqkdXb+lU2ub27G6SeQqDwEIUUsUDK/ARWPfPT3q0iRkMmI22DoPX3r0KWAw9LaJwVcfXqu0pWRSitVVi6x5cdec/nUgiABLIR2wBnNXfIDBSEQFeSQaTYq89XI4PpXXeysjkabfMRxwKAAWbB68UCKMElSoAODkc1Mm4AK7MpA5QHr+NNZR8ny7Vzn1pXsUl9xMi7SzMQMDn3/AArTtg2AQwB7HPNZZCSOrbgMdjVzAByrqCvP0rORalrZGirPkjncPUcUVXjCuBj5gOTlqKyaRd76noFrKskav949+avIi9MDG3nPauasZ1yN2D3Pat2GZdo2nA9a+KPqdS4IxjAOVHPSp4ECuwYd8j6VVM4LD73XtQ84X5uSScnPekylcuzyjaFGM1mhQzgZyCDn61KNjgk9ewzSIgAY46ngHjFVboSlYguolAAwD6j0rEu7EsruVwOoHr/9aukVAWZ5RwOgB61UvCGbGMjoKlrqXHQ4WZ/sl1E5xs3YPuK2rS7iUFUcEjsDWd4hhG2Tjndyabp10k1lCXgUyfdMi8EEcfjWkb7otauzOh/tLy487dy4zx0Aqq8slyAT8seeFBOfrmliV5BvuOUGPlA6/Wm3M4i5BA6gc9qtsiSS2KU4CPx2965XUgZ73gHg5PP8Oea2tQvPJiaUsCT90etYHLSuZFSQou4OWwdnf/8AVXt5PRbqOq9l+Z42b1Uoqmnq/wBBsqGORFzINhJCnB+Ungmq5iXzVP8Ay0BwQeD9TUyR7pCkqnCgYO7gqajiXMm1mZSFKsCue3+RX0Vjw79RrW4Z8MCRj5sN1aljhDjCRsFckZB5BAqQOTbPE5iIZQqluNpprQN5aCSMgsMBVfGSOM5oIvd2YmNyKjsyx9ckZ5xwDWXqvh/TNSg3OqxzEZ86FdoyPUVrbJDGd6tk5Ix1BHWpRO5X5UyByWK+2Pu0pwjNWkrlxk4u6OPGi6vYqv2G4ivUHIRzhgPr/wDXqZdWvrYGO+027iZepibf+YrpQYwVVI0IwWUkYHuKcERYtwVWcAkAHA2/WvPqZXQn5HRTxtaHus54eIbQ4zLqET9MG3NTp4j035cahqDv6Jbnr7d605AhaNyGYhTgF+cfWpYI1hcMsmGKnIDfNtPfNYf2PT/mOhZnNdDNfWVk3PBZ6rOF+87qI/x55qGeC/uY/wB3Fa2pPQuzSMPxHH41sooZm5ZnxklSN2OxpzwkLne24rhuRuI7EiuinldGO+pjPH1ZrscbcaT4ihOI9VGM4ADED+VUxq3ijSpCJQ8gXg703A/QivQioWMHaxc/Kc4IHocUKfLjYyEAqdpG3Ofcf4USyuhJaaChjqqtqclafEa5UBL+0J5wWBxj8DXQ6f450S4Ply3LQE8fOpA/OpLrTba72G5jSbPyZkQY9vp9ayLvwlpNwQQrW6nKkp/CfXHpXFUyXrBnVDNZX1O107UVnG6yu4p4+hAOc1divZInKTJl16nrmvKE8FXVtMH0/UxF/wBNPmXH4ipDY+L7KfMN486k4+aQEE9D16VxVMpqrodsM1pvdnrkWq7RxHx3oGqJtxnAB49K8tRfF+QWihjLZxufGaSXTPFDod15bo+OFT/Gs1lNd9DR5nR7npUl9H94PnPv0qjeXqlsiYNkA/T2rz86J4jJ3DVYyoBy3YH0PFQvoniNQxGoRsB06dfyq/7IrdiY5pTWx6NHdnaNjAkdB6ipH1NkKq6Ordee1ebrbeLLduJYHYD+Ig/jVr+0fGNuNrW9nKME9AePwNEcBXirOJTzCjJ3uemWmpxuvByfWr8V+h6Nz6ZryM6t4lkbnSrRnIxvQkZ9+DUMmueJrRsrp0YB5BGXB/WpeCqa+6XHMKfVntIvArq+QSpHWjxDfCOJTnIK+teP6d4w1q4uI45dNRefvksq/rXQXWo3l2R9oTYMZ+90+gp0Mrq1ZLm0RNXMqcLNasxtTW5uL6WWG8uI17BQCP1qKG81aE/ubmGUns8ZBP45q4ylAF2gFgeSePrineVtVXYpjoMnk+4FfQPL6HKlyniPG122+YSDXdZPybIVAGNxYnPtS/2zq0mP9SfbnNWltCp2uMY+bhcU6C2YOVJyOudvBPtWayzDL7Jf1+vouYzJ7u/uWImcbQOQikZ/Gqq2MbKGKbieQTkkH610Bh3MwZVUDq3QA1G9odpJRQM5BHr6VvTw9Kl8EbGU6s6nxSZThtX2iRwpK/dBxyPU1KI1KOecDnryakmjUuwZMkgfKP6VpWdjI8eZRljxVuVjPUyEi+diVwvU84NAJkOQML2zyK05rcgyIoGF5PHNVvs8kg2DO369qvmuJ2S1KrHBLYyw6jHBpwkyVyE3beuOKsx2mFBf5V6ZwfzpVtmOdgwvcnnNTcLMriQhwMAg85I/SnoXMpyDt68L19jVn7GpXpkD1PWrKWrFcuAvGannVhqLk9CkzTOhVSArDkYyCPQ0QhypwFYewxV+S3kMedqqOOnXiiOCYMpLDcxwc44o5tAceXcqEE5BVQCfvHgfWpNhPysOB1NWnWR1wQQOmCM7qk8ksApUgY6EdqnmvoVZbIrLGpAKoSRyMcmpY9rDBUgY6dTU+JfKJQIB9CKaBtJwgJXnj3qG7jSsOaMRjAxjqc85FFNZsI2APm7A5opIfN2LemX+QoYgqa6rT7hSn6mvGbS5vtGvTbXm7ywSNrDlfoa7/SNR82NCj8dq+MaT1R9Y1bRncQtvBOeO1LtXYSQc9s9zWPBecqCQDWpBc7vvBduOOeTU6AtFcmQtFjuemOwqYLuh8xj8ueh6mofNQFWB8zI6EcA0152lcE5dugwOtV6Cab1RJNKScHj0FMcps5X5scCpXiMPzykK2PlQ8n6n/Csq7nBYgNlm6CpaCLTMPVnXdI7Ywo79M4rK8Ly/u5Um+6x3Icd8807xFOXlSxtf3k8pwAePqfpVe8tJdM0OWS3ZJpkzsCNkMw/z+NdVClzRdzGpV5Zo3b3VIrdOWwO+TXNTav8AaJWRNzD0HJNcitlrGqz+Zd3qWsRzwOTXQWenDTog8Sb5ZE+/uyRjrk/SvTw2Uyn/ABNEefWzVJfu1ceHLSbtrvIRlV7D/PeiAp5hMikqq7sbeSPrUgyjFIt20KGBJ4OByPbiiKchmEaynjeq9AO2Pyr6GnSjShyQVkeHOo6s+ee5Ayog/eANxnPQlD2qF4137fNLqFA4PGKsvmLMeSQoHJGeOnFRt5MW5SUKoM78ZOPwrRGfN0IZCyRMXVlJ4GRnj+tNnWTYRKUcNj5ccBh6H3qcwb8eYRnaOjdF7H61AQIgvzuQflJK5we1MfxbA8j+WC8YcMcqA20hs9KlmZ3Yfu5CAcqQec9/rSgjIjMn3h1YEgEf407DHAOCj8qSOA1JjTvoJI7OgId1AG4PtHXvTGkXywvzKoyS23P4GlmzIQpERGeF3bcMPU1MJJGABhBPOMNznvRbTUFroxgkRIwqrGqgbunBB6fiKfIqCJVgEYbO4LnPy/WmCUHO6F1wTjjjPoafIytCMrwMnlfzH4UbA9UOVBGv7vaDtyU9vrUUoGSEAO1csMndt4xz+dOTZs3DgqMgMvBH+e1PdE2osZQtywJ4yD2pJ6gtCNFTyA6CXn+6w3e2aF3Q4IyzZIYZ4I9fY1P5MaxFVMcjE8gNggfWoSpOQ771XheQNwP9RTTJXRN6inf5iuBJIGBXe3HHvTgVDFHMm4EBgOgHrT3McZG0tuX5Rvbll96jj2Ru7uGYkbcL020imlsyWQqjNiTeo46cfXHrUx8vyc7o3U/LyeAR3/WqZTblwxUMSD8ucj6Uu0Z/eEBGGMBePY47U72JSS0LMhYcOFVOoUtgZHv6GkkkkWXy/JVcjdtBxg9+fSqccUo5IWRG42n+I+vtT3DEMXRCAcEZPB+tO4WTVyVo9is2MA9WB7+9RGZSDiIbz1fPfsDUNzGWJCk9QSSvIPTr3pvkzH5SxyOMYxS5macqWxMXLDK7QAOoOTnFQwiE8xAbh3UcZNSRWsvPIUjggLwDUyWrtG3m5BB52kAMPWk2KySV+pXjtSzAJ+7GemMEGnLbtkgDy+eoFWfK2ldxcjIGSeoq1FbRMjM6j/Y+bt7+9S5Mra5ReEE/OWYr2Azg+tOWBgFZSC4bjIzirywgMFRFJUcHnmntbEQsVLEjAIB61PNfQJIzDDn5i2Cx9M4pRAzFQG5H8WOlaIt1MShnhHbac9KaEQBtoJXHrjj1o5mUo2RWigDFgASRyPm4A96f9nbIZGXAPfmrawrtyFwnBPGSfpVlYlKHy8KcgkY5P41PMCikrFGS1whADSMeOORmka1Yj97nf6Z7VpeQpIQghh1IOAD71H5ajJZgD/nvS5iuVX0KVraiJj8gy3QdSPxrQiUow2koxwAMf1pFXaQY9oPTnigj7vmjjP3if6VDZXw6EN5GN+1gmQOo7/WokiYscEBQM1YuQoBMfzADg9P0qJBuC4CqOpYnvVLYzloxDAQ4C/MF5Oc/pQEXac5UHP51KPMUBY2JweOM5FTMxHDbS4HOVycdqVyr3RWCNGojMfuCKniTaTt3A45PcVEpDsXO0jq3+NSlwY9gXH9fxpMd76hsjAzIGOThVB5JqHbEGITdluQCPSkUsuAQcg4ODkClfZkkBgx6qTQNO3qMLFJAcLyONvX60qMdzDKqepwTmleMlg5DAjI6cCkwj7pG8we2M/rSC6WgjSSLt+f5SeM9vfFM3SGUkHj16A1MiozDDFQRxxk5qIoBKQDiMDkAZNKwt+o6TLR7VII78YH0opoO1lOVA7bvWilew3LXVl7xpokWo2LTRf61Rke/tXEeH7p7eRoJWKuh4x3Fejy/6o/hXlOrf8hxf+un+NfIvdPufWPVHo9jdqQMuD65rVt7jecqwHHHNcfpPRf9010Okf6xP9+pasNaq5v27S43sQo6ZPertvqdvAuYwDIeNx61SvPuSfQVkz/cjqbjUVJXNW+vsDeXDZ9DXN6rrkVtFI/HmkYUZ6VPP91a4bxB/wAfZ+hrejBSdmc9aThByRtaXHcRxG8uHPn3Q4yOQmeueozW2Y1Szc/wmM9s8jkUviX/AJCY/wBxf/QFok/5B8ldl7SSXcyir0nJmHcMkss0o8qMEBg0fOSDgrj61DKZCHIRdrHJYnt3FWYP9bP/AL9VYOkn1avrOh8rbqRHzFeQxRbQcHJYEY+n0qQZZnjVZCCMgn7pXufyplr/AKq5/wA+lWrf/j0f/tp/MU12Ja1GFolDLscqhyQc5APXBqFgmx9wXC8Lkc4PSrS/8ejf9cn/AJ1A3/H5/wAA/pTtqO5A6FVZkMZAO1x/e/8A1UTwZBCscHAZVPOR3q8f9Vef7g/pWZcfeT6ChiVmx5QowMZYEY3jAIU9utPkO3JeVh5o6HnBH8qdJ/r3+q0XP+um/wB4fyoa2ZViErmErvB3dRjvSu8nkqSIWBHRiRg1Yh/4/n+g/lUE33JqH2HJcrVupJguU3AOCNwAbBBHWhiZdzrlX65U96bB/wAep/3RUcf3F/66UmSknqWmdWjGUkwo++T972xSO4ADNJ5cajK/LkHnkfhTJv8AV23/AAL+dWJf+PRPqf50CTIp1xt2+WA3UsOCPaiWHAUvJx/DgZO36elWn+4P+Bf0qvH96H8ad9CmtLleWQFlWKNQPvKcdvSpCo2ho2jbqOSckdwRVpPvv/vH+lVI/wDXH/eP9alMLX0FdNuNhU4zwG5I/rRGjlSMsWHByeQP61F/B+LUq/dT/cNDHFXskSKZIgXjm5U7RgZbH0oJYoc7z/e5xn3qtB1/P+dSz9B9KdxS0ZLgFGWTPy9Ocbh70sSrvdZJCAowMdKin+8v0FRn/Wx/7oqbj35Wy+uw7VlUDaOCDw/vTYo1EyndGVGSCG+8PTFRRf8AHzF9DSL/AMfMX1NC1G90jQIQPlQkikfIc4wPSpYo42csJFw33FCkY+lU/wCE/wC8f51ej+4ajbQS1aQ7aG3HLD1OM7TTfkKL5rABfu7u/rT4v9QfqaZP/rR9B/OkjRvQfH5YMe0blPQjpmnsVO0ncnX+HP4Gkj+7L/10P8qkTqP94UbCvsMBd49oJCryB0/OpkDlvMYHgfw9D7GoX/1Mv+/Tpv8AXD61D1dikr6MmZfkYjKgjk9RUGUEWwb2fHPy4qw/+rT6inR/8fP/AAA/yqehb3syu4hYBWyo67jzTOu7ykDKOMlcmkb/AFD1JYf6s/7n9aT0uJbWFuI2ZPugDG7PrVaPDOCRwDkjsRWhc/8ALL6Gsqf/AF6/WnHUUtCw8ivKRjC/xEGns0YARd4VhyfX2qFvupUt31H+5TJTuri7dseU+UnjGM0qsFIOQcjgY4x9KRPvQ0v8RqXqjRLRsPlIDBu+F+XABpWxyyhd2Or8fhjvVqb/AI8B9T/Ksw/61KaVyftWRPNI7soGGIOcE9qa0iAjg4APfGfwqL+NvpUZ/wBd+BosNJbssFsjIDAngAHjFN3JuJ2sB3A702b7sX1FSp/rPzqWUtkyF40ZVYMVX0HNFNT/AI9x/vH+dFUiG9dT/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19472=[""].join("\n");
var outline_f19_1_19472=null;
var title_f19_1_19473="Technique vertical mattress";
var content_f19_1_19473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Technique for placing a vertical mattress suture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To place a vertical mattress suture, the needle is initially inserted at a distance from the wound edge, exiting through the skin on the opposite side, at an equal distance from the wound edge (far-far). The needle is then rotated 180 degrees in the needle holder and the direction of the suture loop is reversed. On the return, small bites are taken at the epidermal/dermal edges (near-near).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19473=[""].join("\n");
var outline_f19_1_19473=null;
var title_f19_1_19474="Patient information: Hospital-acquired pneumonia (The Basics)";
var content_f19_1_19474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83154\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"         Pneumonia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/47/31473\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/4/22595\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hospital-acquired pneumonia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hospital-acquired-pneumonia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9945205\">",
"      <span class=\"h1\">",
"       What is pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pneumonia is a lung infection that can cause a fever, cough, and trouble breathing (",
"      <a class=\"graphic graphic_figure graphicRef55943 \" href=\"UTD.htm?10/3/10294\">",
"       figure 1",
"      </a>",
"      ). The lung infection is usually caused by bacteria, but it can also be caused by viruses or other germs.",
"     </p>",
"     <p>",
"      Doctors use the term &ldquo;hospital-acquired&rdquo; when a person catches an infection during a hospital stay. Doctors use the term &ldquo;community-acquired&rdquo; when a person catches an infection in their daily life.",
"     </p>",
"     <p>",
"      Hospital-acquired pneumonia is usually more serious than community-acquired pneumonia. That&rsquo;s because people who get hospital-acquired pneumonia are usually sick to start with.",
"     </p>",
"     <p>",
"      One type of hospital-acquired pneumonia happens in people who have a breathing tube and are attached to a breathing machine, called a ventilator. This type of pneumonia is called &ldquo;ventilator-associated pneumonia.&rdquo; Another kind of hospital-acquired pneumonia happens in people who live in a nursing home or other facility. This type of pneumonia is called &ldquo;healthcare-associated pneumonia.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9945237\">",
"      <span class=\"h1\">",
"       What are the symptoms of hospital-acquired pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of hospital-acquired pneumonia include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Coughing up mucus that is yellow or green",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Breathing much faster than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9945252\">",
"      <span class=\"h1\">",
"       Is there a test for hospital-acquired pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for a lung infection, the doctor will do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        Lab tests on a sample of mucus that is coughed up &ndash; Sometimes, the doctor needs to put a tube into the lungs to get a sample of mucus.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9945267\">",
"      <span class=\"h1\">",
"       How is hospital-acquired pneumonia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat hospital-acquired pneumonia with antibiotic medicines. These medicines kill the germs that are causing the infection. People usually get these medicines in their vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      The medicines used to treat hospital-acquired pneumonia are sometimes different than those used to treat community-acquired pneumonia. That&rsquo;s because the germs that cause hospital-acquired pneumonia are more likely to be &ldquo;resistant&rdquo; to medicines. This means they are harder to kill. Because of this, doctors often treat hospital-acquired pneumonia with medicines that work against resistant bacteria. Sometimes, doctors use more than 1 medicine at the same time.",
"     </p>",
"     <p>",
"      Some people with hospital-acquired pneumonia are also treated with extra oxygen to help them breathe more easily. Extra oxygen can be given through 2 small tubes that fit into your nostrils or through a mask that goes over your nose and mouth. People who are very sick sometimes get oxygen through a special breathing tube that goes in the mouth and down into the lungs. The other end of the tube is attached to a breathing machine.",
"     </p>",
"     <p>",
"      Most people start to feel better within a few days of starting treatment. But a cough from pneumonia can last weeks or months after treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9945282\">",
"      <span class=\"h1\">",
"       Can hospital-acquired pneumonia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In the hospital, doctors and nurses do certain things to try to prevent people from getting hospital-acquired pneumonia. For example, they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash their hands often to avoid spreading germs",
"       </li>",
"       <li>",
"        Remove a person&rsquo;s breathing tube as soon as he or she no longer needs it",
"       </li>",
"       <li>",
"        Raise the head of the bed when a person is on a breathing machine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9945297\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/1/19474?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83154 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-33308A762F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19474=[""].join("\n");
var outline_f19_1_19474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945205\">",
"      What is pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945237\">",
"      What are the symptoms of hospital-acquired pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945252\">",
"      Is there a test for hospital-acquired pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945267\">",
"      How is hospital-acquired pneumonia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945282\">",
"      Can hospital-acquired pneumonia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9945297\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"      Pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_1_19475="Electrograms atrial tachycardia";
var content_f19_1_19475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Intracardiac electrograms during atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are surface ECG leads I, II, III, V1, and V6 and intracardiac electrograms form the right ventricular apex (RVA), ablation catheter (AC), and bundle of His (HBE). The AC is located at the site of earliest atrial activity during the tachycardia; the onset of the atrial electrogram at this site (dash line), which is fractionated and prolonged, precedes the onset of the P wave by 35 msec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hasan Garan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19475=[""].join("\n");
var outline_f19_1_19475=null;
var title_f19_1_19476="Balloon dilation of an NSAID-induced ileal stricture";
var content_f19_1_19476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balloon dilation of an NSAID-induced ileal stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Nonsteroidal antiinflammatory drug (NSAID)-induced ileal stricture.",
"    <br/>",
"    (B) Through-the-scope balloon dilation of stricture.",
"    <br/>",
"    (C) Post-dilation appearance of stricture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Louis-Michel Wong Kee Song, MD, FRCP(C).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19476=[""].join("\n");
var outline_f19_1_19476=null;
var title_f19_1_19477="Ethical considerations in effective pain management at the end of life";
var content_f19_1_19477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ethical considerations in effective pain management at the end of life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Vicki Jackson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Lida Nabati, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19477/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/1/19477/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients and families suffer from untreated pain at the end of life. Failure to treat pain effectively can result both from a lack of clinician training in palliative care and also from the fear of violating ethical, moral, and legal tenets in the administration of pain medication to the dying patient. Clinicians often have an exaggerated perception of the risk of hastening death by treating pain with opioids. Furthermore, they are frequently unclear about the distinctions between pain management, sedation for intractable symptoms, physician assisted suicide (PAS), and euthanasia. Physicians are faced with balancing these concerns with their legal duty and moral obligation to treat pain in the suffering patient.",
"   </p>",
"   <p>",
"    Studies of patients in their last week of life reveal that up to 35 percent describe pain as severe or intolerable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/1\">",
"     1",
"    </a>",
"    ]. Quill and Brody define the escalation of pain that is uncontrolled at the end of life as a \"medical emergency\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/2\">",
"     2",
"    </a>",
"    ]. Untreated pain can be devastating to the patient and family not only because of the suffering it produces, but also because it interferes with the ability to complete many important tasks at the end of life. These tasks include, for example, getting legal affairs in order, grieving the loss of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    life, making amends in strained relationships, and saying goodbye to loved ones.",
"   </p>",
"   <p>",
"    Pain management at the end of life is the right of the patient and the duty of the clinician. The World Health Organization states that patients have a right to have their pain treated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/3\">",
"     3",
"    </a>",
"    ]. This is supported by the Supreme Court ruling in Vacco versus Quill, which addressed the use of aggressive palliative care in the last days of life. Justice O'Connor stated in her concurring opinion that \"&hellip;suffering patients have a constitutionally cognizable interest in obtaining relief from the suffering that they may experience in the last days of their lives\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the ethical issues surrounding pain management in patients receiving end of life care. Other ethical issues that arise in patients receiving end of life care (eg, advance care planning, withholding and withdrawing care, physician assisted suicide and euthanasia), and principles of pain management at the end of life are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2650?source=see_link&amp;anchor=H12#H12\">",
"     \"End of life considerations for heart failure patients\", section on 'Pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36694?source=see_link&amp;anchor=H6#H6\">",
"     \"Palliative care: End-stage renal disease\", section on 'Pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEGAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians are unclear about how aggressive palliative care differs from PAS and euthanasia. Palliative care is a comprehensive approach to treating physical, spiritual, and psychological suffering in a patient at the end of life. While this may include prescribing pain medication that carries with it a small risk of hastening death, any hastening of death is not the intention of the treating clinician. The use of medication intended to treat pain or relieve discomfort is legal in all states.",
"   </p>",
"   <p>",
"    In contrast, PAS involves supplying a patient with the means, usually pharmacologic, to end his or her life when desired. In the US, PAS is illegal in all states except Oregon, Washington, and Montana. Euthanasia requires a clinician to physically administer a medication with the intent of causing death and is illegal in all states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most clinicians agree that patients should have their pain treated at the end of life, but many do not treat this pain for fear of the legal repercussions of possibly hastening death. The Court addressed the legality of aggressive palliative care explicitly in the Vacco versus Quill ruling. Justice O'Connor states, \"The parties and the amici agree that in the States a patient who is suffering from a terminal illness and who is experiencing great pain has no legal barriers to obtaining medication, from qualified physicians, to alleviate suffering, even to the point of causing unconsciousness and hastening death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No legal barrier exists to treating pain; in fact, there is a legal risk to clinicians who do not effectively treat pain. In June 2001, a lawsuit was successfully prosecuted in California against a physician who inadequately treated a patient for pain. The jury decided that the doctor's failure to treat the elderly man's pain violated California's elder abuse statute and awarded the family $1.5 million dollars.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRINCIPLE OF DOUBLE EFFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethical consensus exists in the standard treatment of pain at the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/5\">",
"     5",
"    </a>",
"    ]. Religious groups have also addressed this issue. The Catechism of the Catholic Church states, \"Even if death is thought imminent, the ordinary care owed to a sick person cannot be legitimately interrupted. The use of painkillers to alleviate the sufferings of the dying, even at the risk of shortening their days, can be morally in conformity with human dignity if death is not willed as either an end or a means, but only foreseen and tolerated as inevitable. Palliative care is a special form of disinterested charity. As such, it should be encouraged\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the position of the Catholic Church and the Supreme Court is that aggressive treatment of pain at the end of life is legally and morally acceptable even if death is hastened, provided the intention of the action (administering sedating medication) is to relieve pain and not to cause death. This is the principle of double effect (PDE), a concept that originated in the Catholic Church. This principle stipulates that the action taken (administering medication to relieve pain) is morally good or neutral, the intended outcome (relief of pain) is important enough to justify the unlikely but possible bad effect (death) and efforts are undertaken to minimize risk of the bad effect, and that the unintended effect is not the means to achieve the desired effect.",
"   </p>",
"   <p>",
"    A classic example of PDE is the following: a physician may find it morally unacceptable to directly abort a fetus, yet may find it morally acceptable to remove a diseased uterus that may contain a fetus to save the life of a pregnant woman. The physician does not intend to cause the death of the fetus, although it is expected. The key element of PDE is that the intentions of the actor are only good, even if the bad effect is foreseen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/7\">",
"     7",
"    </a>",
"    ]. The PDE is often invoked in writings about the treatment of pain at the end of life.",
"   </p>",
"   <p>",
"    The bioethical principle of double effect is important to patients and to the clinicians who care for these individuals. As Quill states, \"To the extent that the principle allows patients, families, and clinicians to respond in an ethically and clinically responsible way to palliative care emergencies without violating the fundamental values of any of the participants, it (PDE) should be used and protected\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MYTHS AND MISCONCEPTIONS ABOUT OPIOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PDE would only need to be invoked by The Supreme Court and the Catholic Church if the treatment of pain frequently carried with it a substantial risk of hastened death. In truth, opioids are unlikely to hasten death if used in an appropriate manner by a skilled clinician.",
"   </p>",
"   <p>",
"    Opioids have multiple desirable and undesirable effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .) Opioids provide analgesia, but at increased doses may cause sedation and even respiratory depression. Respiratory depression does not occur in isolation, but always in the context of sedation and mental clouding. These precursors to respiratory depression allow for a careful reversal of the opioid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    if necessary.",
"   </p>",
"   <p>",
"    The risk of respiratory depression is of greatest concern in patients who are opioid naive and require large doses of medication to treat severe pain. With continuous use of opioids, sedation and respiratory depression are effects to which patients quickly develop tolerance. Nevertheless, it is important not to gloss over this risk which, while rare, is not nonexistent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Respiratory depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a great deal of clinical experience using opioids in palliative care and hospice settings. One investigator reported on the clinical experience using opioids in hospice patients at the Sir Michael Sobell House in Great Britain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/9\">",
"     9",
"    </a>",
"    ]. He found that respiratory depression was rarely seen in patients who required opioids for pain because pain was a powerful stimulus to the respiratory drive. He also pointed out a phenomenon widely recognized by clinicians in the field: \"the correct use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is more likely to prolong a patient's life&hellip;because he is more rested and pain-free\".",
"   </p>",
"   <p>",
"    The risks associated with the use of opioids are best thought of in the same way clinicians weigh the risks and benefits of any intervention. Let us consider, for example, a patient who requires a thoracentesis to alleviate dyspnea related to a pleural effusion. The patient has a risk of pneumothorax and possible death as a result of the procedure. This is a very uncommon adverse event when the procedure is done by a skilled clinician. The benefit of the procedure may be to greatly decrease the dyspnea caused by the pleural effusion. Clinicians would not avoid the thoracentesis because it carries with it a small risk of an adverse event when the benefits to relieve suffering are so great. They would, however, attempt to reduce the chance of these events as much as possible and inform the patient of these risks.",
"   </p>",
"   <p>",
"    The same is true of the treatment of pain at the end of life. Treatment with opioids carries with it a very small but real chance of respiratory depression. This risk, however, does not outweigh the benefit of giving the drug. In fact, if the adverse event does occur, it is far easier to reverse than those associated with many other interventions.",
"   </p>",
"   <p>",
"    Appropriate use of opioids to treat pain at the end of life would include the use of intermittent doses as needed for intermittent symptoms, and the careful titration of long-acting opioid preparations or continuous infusion of opioids for continuous pain. The relatively common practice of initiating opioid therapy with continuous infusion of opioids with a broad range of &ldquo;as needed&rdquo; doses for titration in opioid-naive patients is discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SEDATION FOR INTRACTABLE SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With aggressive palliative care, acceptable pain relief can be provided to 95 to 98 percent of patients at the end of life. Unfortunately, there is a minority of patients, 2 to 5 percent, in which we can not achieve adequate pain control despite expert pain management without giving pain medication to the point of sedation or giving other medications with the intention of inducing sedation to relieve suffering (palliative sedation) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PDE is more applicable in the case of sedation for intractable symptoms than it is in the standard treatment of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/11\">",
"     11",
"    </a>",
"    ]. Just as with standard pain management, clinicians desire and intend not to hasten death, but rather to relieve suffering when implementing palliative sedation. The key issue is that the medications are administered with the intent of relieving some sort of uncontrolled distress (eg, pain, dyspnea, delirium), and the sedating medication (often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) is titrated carefully to effect. Once the desired effect is achieved, the sedation is no longer increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of managing common non-pain symptoms in palliative care\", section on 'Palliative sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies indicate that, when used appropriately, palliative sedation does not hasten the death of palliative care patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Given that randomized trials would not be ethical in this situation, the best data come from a population-based study that examined survival in two cohorts of hospice patients, one submitted to palliative sedation (predominantly light sedation with neuroleptics and benzodiazepines, 25 percent received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ), and the other managed per routine hospice practice [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19477/abstract/12\">",
"     12",
"    </a>",
"    ]. Even when matched for adverse prognostic variables, sedated patients did not have an accelerated demise. These data support the view that palliative sedation does not need the PDE to justify its use for the management of refractory symptoms from an ethical point of view.",
"   </p>",
"   <p>",
"    Depending on their underlying condition, patients may survive sedated for days to many weeks. Titration to effect is what distinguishes sedation for intractable symptoms from euthanasia and justifies the legal, ethical, and moral framework for sedation for intractable symptoms as an alternative to PAS or euthanasia.",
"   </p>",
"   <p>",
"    There is wide variation in how the practice of palliative sedation is performed. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of managing common non-pain symptoms in palliative care\", section on 'Palliative sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pain at the end of life is the right of the patient and a moral duty, as well as legal obligation, of the clinician caring for the suffering. Myths and misconceptions about the risks associated with the use of opioids abound in the literature and in clinical practice, as well as in the lay public. The small risk of respiratory depression that opioids carry when used appropriately does not justify withholding their use in treatment of pain and other intractable symptoms at the end of life.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/1\">",
"      Ventafridda V, Ripamonti C, De Conno F, et al. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/2\">",
"      Quill TE, Brody RV. 'You promised me I wouldn't die like this!' A bad death as a medical emergency. Arch Intern Med 1995; 155:1250.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, Cancer Pain Relief and Palliative Care. Geneva. World Health Organization, 1990.",
"    </li>",
"    <li>",
"     Vacco v. Quill, 117 S.Ct. 2293 (1997).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/5\">",
"      Quill TE, Lee BC, Nunn S. Palliative treatments of last resort: choosing the least harmful alternative. University of Pennsylvania Center for Bioethics Assisted Suicide Consensus Panel. Ann Intern Med 2000; 132:488.",
"     </a>",
"    </li>",
"    <li>",
"     Catechism of the Catholic Church. 1994. Part Three, Life in Christ, Section 2, Chapter 2, Article 5. Pauline, St. Paul Books and Media.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/7\">",
"      Fohr SA. The double effect of pain medication: separating myth from reality. J Palliat Med 1998; 1:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/8\">",
"      Quill TE. Principle of double effect and end-of-life pain management: additional myths and a limited role. J Palliat Med 1998; 1:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/9\">",
"      Twycross RG. Ethical and clinical aspects of pain treatment in cancer patients. Acta Anaesthesiol Scand Suppl 1982; 74:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/10\">",
"      Verkerk M, van Wijlick E, Legemaate J, de Graeff A. A national guideline for palliative sedation in the Netherlands. J Pain Symptom Manage 2007; 34:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/11\">",
"      Quill TE, Lo B, Brock DW. Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA 1997; 278:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/12\">",
"      Maltoni M, Pittureri C, Scarpi E, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol 2009; 20:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/13\">",
"      Chiu TY, Hu WY, Lue BH, et al. Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 2001; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/14\">",
"      Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 2003; 163:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/15\">",
"      Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 2001; 21:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19477/abstract/16\">",
"      Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 2012; 30:1378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2201 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.15-EA80EF0749-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19477=[""].join("\n");
var outline_f19_1_19477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEGAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRINCIPLE OF DOUBLE EFFECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MYTHS AND MISCONCEPTIONS ABOUT OPIOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SEDATION FOR INTRACTABLE SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36694?source=related_link\">",
"      Palliative care: End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_1_19478="Esophageal tumor staging EUS";
var content_f19_1_19478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Esophageal tumor staging with endoscopic ultrasound (EUS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Superficial esophageal carcinoma (T1 tumor) extending into the submucosa (third hyperechoic layer), but not into the muscularis propria (fourth layer). Panel B: Esophageal tumor going into the muscularis propria (fourth hypoechoic layer) but not through, defining a T2 lesion by EUS criteria. Panel C: Carcinoma of the esophagus extending through the esophageal wall and invading the adventitia (fifth layer) (T3 tumor). Panel D: EUS image of an esophageal tumor going through the esophageal wall and extending into the pleural space, defining the tumor as a T4 lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19478=[""].join("\n");
var outline_f19_1_19478=null;
var title_f19_1_19479="Pancoast tumor MRI I";
var content_f19_1_19479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56298%7EPULM%2F64987%7EPULM%2F75753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56298%7EPULM%2F64987%7EPULM%2F75753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1-weighted section through the lung mass shows extension through the apical fat pad into the base of the neck (white arrow). The mass partially surrounds a patent left subclavian artery (black arrow) and obliterates the tissue plane containing the brachial plexus. The left brachiocephalic vein is occluded and cannot be seen. A corresponding section from the right side of the neck (next figure) is included for comparison.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uninvolved right lung in a patient with a left Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A section from the uninvolved right side of the neck is included for comparison with the previous figure. There is no invasion into the base of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted image shows a right-sided Pancoast tumor with vertebral destruction (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19479=[""].join("\n");
var outline_f19_1_19479=null;
var title_f19_1_19480="Characteristics of pressure ulcers by stage";
var content_f19_1_19480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Characteristics of pressure ulcers by stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 681px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These illustrations highlight the characteristics of the stages of pressure ulcers as defined by the National Pressure Ulcer Advisory Panel. Each panel demonstrates the clinical appearance of the involved skin as well as the cross section of the depth of injury. Most pressure ulcers are associated with an underlying bony prominence. As illustrated by Suspected deep tissue injury, there is always the potential for deeper tissue damage than originally appreciated. This is due to the \"tip of the iceberg\" phenomenon, as soft tissues are more susceptible to injury than skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on definitions from National Pressure Ulcer Advisory Panel. www.npuap.org (Accessed on December 2, 2008)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19480=[""].join("\n");
var outline_f19_1_19480=null;
var title_f19_1_19481="Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors";
var content_f19_1_19481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Ching-Hon Pui, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19481/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/1/19481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Catabolism of the nucleic acids to uric acid leads to hyperuricemia, and the marked increase in uric acid excretion can result in the precipitation of uric acid in the renal tubules and acute renal failure. Hyperphosphatemia with calcium phosphate deposition in the renal tubules can also cause renal failure.",
"   </p>",
"   <p>",
"    TLS most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas (particularly the Burkitt subtype) and acute lymphoblastic leukemia. However, TLS can occur spontaneously and with other tumor types that have a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy.",
"   </p>",
"   <p>",
"    The pathogenesis, definition, classification, risk factors, etiology, and clinical presentation of TLS will be reviewed here. Prevention and treatment of TLS are discussed elsewhere, as are issues related to treatment of the particular malignancies that are associated with TLS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link\">",
"     \"Tumor lysis syndrome: Prevention and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Tumor lysis syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the complications of acute myeloid leukemia\", section on 'Tumor lysis syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491545\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of a malignancy with a high proliferative rate, large tumor burden,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high sensitivity to treatment, initiation of cytotoxic chemotherapy, cytolytic antibody therapy, radiation therapy, or sometimes glucocorticoid therapy alone can result in the rapid lysis of tumor cells. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Etiology and risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This releases massive quantities of intracellular contents (potassium, phosphate, and nucleic acids that can be metabolized to uric acid) into the systemic circulation. The metabolic consequences include hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute renal failure. High levels of both uric acid and phosphate increase the severity of acute kidney injury because uric acid precipitates readily in the presence of calcium phosphate crystals, and calcium phosphate precipitates readily in the presence of uric acid crystals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491572\">",
"    <span class=\"h2\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia is a consequence of the catabolism of purine nucleic acids to hypoxanthine and xanthine and then to uric acid via the enzyme xanthine oxidase (",
"    <a class=\"graphic graphic_figure graphicRef79178 \" href=\"UTD.htm?21/22/21869\">",
"     figure 1",
"    </a>",
"    ). Uric acid is poorly soluble in water, particularly in the usually acidic environment in the distal tubules and collecting system of the kidney. Overproduction and overexcretion of uric acid in TLS can lead to crystal precipitation and deposition in the renal tubules, and acute uric acid nephropathy with acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the development of effective hypouricemic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ), hyperuricemia is no longer the major metabolic complication associated with TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21715509#H21715509\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Hypouricemic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    As an example, in a report of 102 patients with intermediate to high-grade non-Hodgkin lymphoma who received aggressive combination chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    prophylaxis, laboratory abnormalities developed in 42 percent of the patients, but only 6 percent developed \"clinical\" TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1\">",
"     1",
"    </a>",
"    ]. With the use of allopurinol, the serum uric acid concentration rose by more than 25 percent in only 28 patients, and the peak exceeded the upper limit of normal (ULN, 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [476",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    in only nine patients and exceeded 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (893",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in only three patients, one of whom developed acute renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491579\">",
"    <span class=\"h2\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphorus concentration in malignant cells is up to four times higher than in normal cells. Thus, rapid tumor breakdown often leads to hyperphosphatemia which can cause secondary hypocalcemia. When the calcium concentration times phosphate concentration (the calcium phosphate product) exceeds 60",
"    <span class=\"nowrap\">",
"     mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    there is an increased risk of calcium phosphate precipitation in the renal tubules, which can lead to renal failure. In addition, precipitation in the heart may lead to cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link\">",
"     \"Overview of the causes and treatment of hyperphosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the widespread use of hypouricemic agents, calcium phosphate deposition (nephrocalcinosis) rather than hyperuricemia has become the major mechanism of acute renal failure in TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21715509#H21715509\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Hypouricemic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491586\">",
"    <span class=\"h2\">",
"     Xanthinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    blocks the catabolism of hypoxanthine and xanthine, leading to an increase in the levels of these metabolites (",
"    <a class=\"graphic graphic_figure graphicRef79178 \" href=\"UTD.htm?21/22/21869\">",
"     figure 1",
"    </a>",
"    ). Xanthine is much less soluble than uric acid, and urinary alkalinization increases the solubility of xanthine much less than the solubility of uric acid because the pKa is much higher for xanthine (7.4 versus 5.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients with massive TLS who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    are at risk for xanthine precipitation in the tubules, resulting in acute renal failure and xanthine stone formation, despite adequate hydration and urinary alkalinization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. In contrast to the effect of allopurinol, xanthine excretion is not increased by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    (recombinant urate oxidase), which is now preferred in most patients at high risk for TLS. Rasburicase promotes the degradation of uric acid to the much more water-soluble compound allantoin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712072#H21712072\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Rasburicase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491877\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with TLS largely reflect the associated metabolic abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia). They include nausea, vomiting, diarrhea, anorexia, lethargy, hematuria, heart failure, cardiac dysrhythmias, seizures, muscle cramps, tetany, syncope, and possible sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute uric acid or calcium phosphate deposition does not usually cause symptoms referable to the urinary tract, although flank pain can occur if there is renal pelvic or ureteral stone formation. The urinalysis classically shows many uric acid crystals or amorphous urates in an acid urine (",
"    <a class=\"graphic graphic_picture graphicRef61827 \" href=\"UTD.htm?10/50/11040\">",
"     picture 1",
"    </a>",
"    ), but is occasionally relatively normal due to lack of output from the obstructed nephrons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a general consensus that TLS represents a set of metabolic complications that arise from treatment of a rapidly proliferating and drug-sensitive neoplasm, there have been relatively few attempts to specifically define the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The 1993 Hande-Garrow classification system distinguished between laboratory versus clinical TLS within four days of initial anticancer treatment, but did not take into account patients who already had abnormal laboratory values prior to treatment or those who developed metabolic abnormalities at a later time point [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cairo-Bishop definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cairo-Bishop definition, proposed in 2004, provided specific laboratory criteria for the diagnosis of TLS both at presentation and within seven days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/13\">",
"     13",
"    </a>",
"    ]. It also incorporated a grading system to help delineate the degree of severity of TLS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory TLS (TLS) was defined as any two or more abnormal serum values, as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef59424 \" href=\"UTD.htm?19/28/19915\">",
"       table 1",
"      </a>",
"      ), present within three days before or seven days after instituting chemotherapy in the setting of adequate hydration (with or without alkalinization) and use of a hypouricemic agent.",
"     </li>",
"     <li>",
"      Clinical TLS (CTLS) was defined as laboratory TLS plus one or more of the following that was not directly or probably attributable to a therapeutic agent: increased serum creatinine concentration (&ge;1.5 times the upper limit of normal [ULN]), cardiac",
"      <span class=\"nowrap\">",
"       arrhythmia/sudden",
"      </span>",
"      death, or a seizure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A grading system for severity of TLS (on a scale from zero to five) in patients with laboratory TLS was based on the degree of elevation in serum creatinine, the presence and type of cardiac arrhythmia, and the presence and severity of seizures (",
"    <a class=\"graphic graphic_table graphicRef72208 \" href=\"UTD.htm?20/59/21436\">",
"     table 2",
"    </a>",
"    ). This scheme for grading severity is far more useful than the most recent modification of the widely used NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03), which only grades TLS as grade 3 (present), grade 4 (life-threatening consequences; urgent intervention indicated) or grade 5 (death) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cairo-Bishop classification has been adopted by the Children's Oncology Group for use in treatment protocols for advanced stage lymphoma and by an international panel of experts assembled to establish evidence-based guidelines for prevention and treatment of pediatric and adult TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link\">",
"     \"Tumor lysis syndrome: Prevention and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .) In a review, Howard et al suggested that two or more laboratory abnormalities should be present simultaneously to define laboratory TLS and that any symptomatic hypocalcemia should constitute clinical TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of TLS is greatest in patients treated for hematologic malignancies but is not uniform among these disorders (",
"    <a class=\"graphic graphic_table graphicRef59645 \" href=\"UTD.htm?1/24/1421\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Certain intrinsic tumor-related factors are associated with a higher risk. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,11,13,15-19\">",
"     1,11,13,15-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High tumor cell proliferation rate",
"     </li>",
"     <li>",
"      Chemosensitivity of the malignancy",
"     </li>",
"     <li>",
"      Large tumor burden, as manifested by bulky disease &gt;10 cm in diameter",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a white blood cell count &gt;50,000 per microL, a pretreatment serum lactate dehydrogenase (LDH) more than two times the upper limit of normal, organ infiltration, or bone marrow involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also clinical features that predispose to the development of TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,11,13,15,16,18\">",
"     1,11,13,15,16,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pretreatment hyperuricemia (serum uric acid &gt;7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [446",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      or hyperphosphatemia",
"     </li>",
"     <li>",
"      A preexisting nephropathy or exposure to nephrotoxins",
"     </li>",
"     <li>",
"      Oliguria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acidic urine",
"     </li>",
"     <li>",
"      Dehydration, volume depletion, or inadequate hydration during treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of impaired renal function as a risk factor for TLS was illustrated in a series of 102 patients with high-grade NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with a baseline serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    had a markedly higher rate of clinical TLS than did those with a lower serum creatinine (36 versus 2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumors most frequently associated with tumor lysis syndrome (TLS) are clinically aggressive non-Hodgkin lymphomas (NHLs) and acute lymphoblastic leukemia (ALL), particularly Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59645 \" href=\"UTD.htm?1/24/1421\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,17,20-24\">",
"     1,17,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of TLS in these patients can be illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the series cited above of 102 adults with high-grade NHL, most of whom received prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      alone, the overall incidence of TLS was 42 percent and 6 percent developed \"clinical\" TLS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1\">",
"       1",
"      </a>",
"      ]. Clinical TLS was defined in this series as serum potassium &gt;6.0",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      serum creatinine &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [221",
"      <span class=\"nowrap\">",
"       micromol/L],",
"      </span>",
"      serum calcium &le;6.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.5",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      the development of a life-threatening arrhythmia, or sudden death.",
"     </li>",
"     <li>",
"      The incidence of TLS was assessed in a series of children with advanced stage Burkitt's",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia",
"      </span>",
"      who were enrolled in two multicenter trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/17\">",
"       17",
"      </a>",
"      ]. All were treated with aggressive intravenous hydration, urinary alkalinization (urine pH 7), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      , which was not available at that time. Among the 218 evaluable children with Burkitt ALL or stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      Burkitt lymphoma with a high pretreatment serum LDH (&ge;500",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      [8.3",
"      <span class=\"nowrap\">",
"       kat/L]),",
"      </span>",
"      TLS (laboratory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical) developed in 16.1 percent and anuria in 9.2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other hematologic malignancies that are less commonly associated with TLS include other clinically aggressive lymphomas such as anaplastic large cell lymphoma, T-cell or B-cell precursor ALL, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and plasma cell disorders, including multiple myeloma and isolated plasmacytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/1,18,25-29\">",
"     1,18,25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of TLS in AML was addressed in a single institution series of 772 adult patients who received induction chemotherapy between 1980 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/18\">",
"     18",
"    </a>",
"    ]. Prophylactic measures included intravenous hydration and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    . Overall, 130 (17 percent) developed TLS (5 percent clinical, 12 percent laboratory according to the Cairo-Bishop definition described above). On multivariate analysis, the following pretreatment laboratory findings were independent risk factors for TLS: serum LDH above laboratory normal values, serum creatinine &ge;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    pretreatment serum uric acid &gt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (446",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and white blood cell (WBC) count",
"    <span class=\"nowrap\">",
"     &ge;25,000/microL.",
"    </span>",
"    These four factors were used to develop a scoring system to predict the development of TLS in AML. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Risk stratification in acute leukemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most cases of TLS in patients with hematologic malignancies follow treatment with combination cytotoxic chemotherapy. However, TLS has also been described in case reports with glucocorticoids alone in patients with NHL and ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], with therapeutic monoclonal antibodies (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with high-grade NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/21-23\">",
"     21-23",
"    </a>",
"    ] but also",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]), with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/32\">",
"     32",
"    </a>",
"    ], and with radiation therapy alone for NHL and ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/24,33\">",
"     24,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Solid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLS has been rarely described after treatment of nonhematologic solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19,34\">",
"     19,34",
"    </a>",
"    ]. These include breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], small cell carcinoma (mostly involving the lung) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19,35\">",
"     19,35",
"    </a>",
"    ], neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/35\">",
"     35",
"    </a>",
"    ], germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19,38\">",
"     19,38",
"    </a>",
"    ], medulloblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19\">",
"     19",
"    </a>",
"    ], sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19,39\">",
"     19,39",
"    </a>",
"    ], ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], squamous cell carcinoma of the vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/42\">",
"     42",
"    </a>",
"    ], metastatic colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/43\">",
"     43",
"    </a>",
"    ], urothelial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/44\">",
"     44",
"    </a>",
"    ], gastrointestinal stromal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/45\">",
"     45",
"    </a>",
"    ], melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19\">",
"     19",
"    </a>",
"    ], and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Spontaneous TLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous acute renal failure associated with marked hyperuricemia prior to the initiation of therapy has been described in NHL and acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/20,25,46,47\">",
"     20,25,46,47",
"    </a>",
"    ], and in at least one patient with inflammatory breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/48\">",
"     48",
"    </a>",
"    ]. The actual incidence of this syndrome is difficult to ascertain. In a series of 33 patients with aggressive or highly aggressive NHL, three had marked hyperuricemia (plasma uric acid concentration &gt;17",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1012",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    and acute renal failure requiring hemodialysis prior to the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, spontaneous TLS is associated with hyperuricemia but frequently without hyperphosphatemia. It has been postulated that rapidly growing neoplasms with high cell turnover rates produce high serum uric acid levels through rapid nucleoprotein turnover but that the tumor is able to reutilize released phosphorus for resynthesis of new tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, TLS after chemotherapy is due to cell destruction in the absence of reuptake of phosphorus, and thus, hyperphosphatemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, an international expert panel published evidence-based guidelines for the prevention and management of TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/11\">",
"     11",
"    </a>",
"    ], which were subsequently refined and updated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"     15",
"    </a>",
"    ]. A risk stratification system for TLS was proposed using the type of malignancy, the burden of disease, treatment, expected response to treatment, and renal function (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 4",
"    </a>",
"    ). The recommended therapy varied according to the risk category. Both the stratification system and the specific treatment recommendations were defined by consensus opinion; neither has been validated in a prospectively defined group of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21709492\">",
"    <span class=\"h2\">",
"     High-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Included in the high-risk group (&gt;5 percent risk of TLS) are [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All Burkitt leukemia, stage III or IV Burkitt lymphoma or early stage Burkitt lymphoma with serum LDH level two or more times the upper limit of normal (&ge;2xULN)",
"     </li>",
"     <li>",
"      Other ALL with a WBC &ge;100,000 per microL",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum LDH level &ge;2X ULN",
"     </li>",
"     <li>",
"      AML with WBC &ge;100,000 per microL",
"     </li>",
"     <li>",
"      Stage III or IV lymphoblastic lymphoma or early stage lymphoblastic lymphoma with serum LDH level two or more times the upper limit of normal (&ge;2X ULN)",
"     </li>",
"     <li>",
"      Adult T-cell",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia,",
"      </span>",
"      diffuse large B-cell lymphoma, peripheral T-cell lymphoma, transformed lymphoma, or mantle cell lymphoma with serum LDH level above the ULN",
"      <strong>",
"       and",
"      </strong>",
"      a bulky tumor mass",
"     </li>",
"     <li>",
"      Stage III or IV childhood diffuse large B-cell lymphoma with serum LDH level &ge;2X ULN",
"     </li>",
"     <li>",
"      Patients with intermediate risk disease (see below) with renal dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal involvement, or uric acid, potassium, or phosphate levels above the ULN",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In keeping with the recommendations of the expert panel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/11\">",
"     11",
"    </a>",
"    ], we recommend that all patients that fit into these high-risk categories receive aggressive IV hydration and prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    prior to treatment initiation (unless they have G6PD deficiency) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712072#H21712072\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Rasburicase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712086#H21712086\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Contraindications and restrictions'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other definitions for high-risk have been proposed. As an example, the SFCE (French Society Against Cancers and Leukemias of Children and Adolescents) classifies children as high-risk for TLS if they have one of the following: leukocyte count &gt;50,000 per microL, large tumor burden (major hepatomegaly or splenomegaly, lymph nodes or a mediastinal mass &gt;5 cm), T-cell or B-cell lymphoma, L3 ALL (Burkitt leukemia), AML, any other leukemia with serum LDH &gt;2x the ULN, creatinine &gt;ULN for age and weight, uric acid &ge;300",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    if &le;10 years of age, or &ge;350",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    if &gt;10 years old, and serum phosphorus level &gt;2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/49\">",
"     49",
"    </a>",
"    ]. They recommend that all such patients receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21709499\">",
"    <span class=\"h2\">",
"     Intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intermediate-risk group (risk of TLS 1 to 5 percent) includes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T-cell",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia,",
"      </span>",
"      diffuse large B-cell lymphoma, peripheral T-cell lymphoma, transformed lymphoma, or mantle cell lymphoma with serum LDH level above ULN but",
"      <strong>",
"       without",
"      </strong>",
"      bulky disease",
"     </li>",
"     <li>",
"      Stage III or IV childhood anaplastic large cell lymphoma with serum LDH level &lt;2X ULN",
"     </li>",
"     <li>",
"      Stage III or IV childhood diffuse large B-cell lymphoma with serum LDH level &ge;2X ULN",
"     </li>",
"     <li>",
"      Early stage Burkitt lymphoma with serum LDH level &lt;2X ULN",
"     </li>",
"     <li>",
"      ALL with WBC",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"      and serum LDH level &lt;2X ULN",
"     </li>",
"     <li>",
"      AML with WBC 25,000 to",
"      <span class=\"nowrap\">",
"       100,000/microL,",
"      </span>",
"      or AML with",
"      <span class=\"nowrap\">",
"       WBC&lt;25,000/microL",
"      </span>",
"      and LDH &ge; 2X ULN",
"     </li>",
"     <li>",
"      Early stage lymphoblastic lymphoma with serum LDH level &lt;2X ULN",
"     </li>",
"     <li>",
"      Chronic lymphocytic",
"      <span class=\"nowrap\">",
"       leukemia/small",
"      </span>",
"      lymphocytic lymphoma",
"      <span class=\"nowrap\">",
"       (CLL/SLL)",
"      </span>",
"      treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with a high WBC",
"      <span class=\"nowrap\">",
"       (&ge;50,000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Rare bulky solid tumors that are highly sensitive to chemotherapy (such as neuroblastoma, germ cell cancer, small cell lung cancer)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is disagreement among experts as to the overall risk of TLS with",
"    <span class=\"nowrap\">",
"     CLL/SLL.",
"    </span>",
"    Some clinicians consider that patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    and a WBC count between 10,000 and",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    are at relatively low risk for TLS, regardless of treatment, while others consider all patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    to be at risk for TLS if they have a WBC &ge;50,000, or low circulating WBC counts and a packed marrow, particularly if they are older and have borderline renal function. Although initially reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , there are now several reports of TLS occurring after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    or flavopiridol therapy for fludarabine-refractory CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In keeping with the recommendations of the expert panel, we generally use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    for prophylaxis in most of these patients in the absence of pretreatment hyperuricemia. An alternative approach is administration of a single dose of rasburicase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712058#H21712058\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Allopurinol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712079#H21712079\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Dosing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians routinely place all",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    prior to initial chemotherapy, and treatment protocols from the Cancer and Leukemia Group B (CALGB) routinely recommend allopurinol 300 mg daily for the first 14 days of chemotherapy, thereafter at the clinician's discretion. However, as noted above, patients with CLL and a WBC 10,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    have a relatively low risk of TLS, regardless of treatment, and others approach these patients with hydration and close monitoring rather than routine prophylaxis with any hypouricemic agent. In our view, treatment of these patients should be individualized based upon circulating WBC count, status of the bone marrow, and renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21709506\">",
"    <span class=\"h2\">",
"     Low-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at low risk for TLS (&lt;1 percent risk) include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AML with WBC",
"      <span class=\"nowrap\">",
"       &lt;25,000/microL",
"      </span>",
"      and serum LDH level &lt;2X ULN",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CLL/SLL",
"      </span>",
"      with a WBC",
"      <span class=\"nowrap\">",
"       &le;50,000/microL",
"      </span>",
"      and not treated with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"        fludarabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"        rituximab",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      Multiple myeloma and CML",
"     </li>",
"     <li>",
"      Other adult NHL that do not meet the criteria for high-risk of intermediate risk, with serum LDH level within normal limits",
"     </li>",
"     <li>",
"      Other solid tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally recommend hydration but do not administer any form of prophylactic hypouricemic therapy or phosphate binders to patients in the low-risk category. This is in agreement with the expert panel recommendation for a \"watch and wait\" approach with close monitoring rather than routine prophylaxis in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21715371#H21715371\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk stratification in acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictive models for the probability of TLS in patients treated for AML or pediatric ALL have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/18,52,53\">",
"     18,52,53",
"    </a>",
"    ]. As previously described, a scoring system to predict TLS was developed and validated in a series of 772 adult patients with AML treated at a single institution over a 22-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hematologic malignancies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patients were randomly divided into two groups; the prognostic model was developed in one group and validated in the other. In multivariate analysis, four pretreatment laboratory findings were independent risk factors for TLS: serum LDH above laboratory normal values, serum creatinine &ge;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    pretreatment serum uric acid &gt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (446",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and white blood cell (WBC) count",
"    <span class=\"nowrap\">",
"     &ge;25,000/microL.",
"    </span>",
"    FAB classification was not an independent predictor of TLS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The authors assigned a point value to these factors and developed a scoring system to predict the probability of clinical TLS (",
"    <a class=\"graphic graphic_table graphicRef68256 \" href=\"UTD.htm?15/55/16252\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score 0 &mdash; 0 percent",
"     </li>",
"     <li>",
"      Score 1 &mdash; 1.4 percent",
"     </li>",
"     <li>",
"      Score 2 &mdash; 4.1 percent",
"     </li>",
"     <li>",
"      Score 3 &mdash; 11.5 percent",
"     </li>",
"     <li>",
"      Score 4 &mdash; 17.8 percent",
"     </li>",
"     <li>",
"      Score 5 &mdash; 36.8 percent",
"     </li>",
"     <li>",
"      Score 6 &mdash; 41.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors suggested that the model might permit risk-adapted management of TLS in AML, specifically the selection of those high-risk patients who should receive prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    . &nbsp;However, they did not make a specific recommendation as to which score should be used as the cutoff for the use of rasburicase versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    . In general, these models are complex, and they lack standardized guidelines for supportive care guidelines. We generally prefer the risk stratification system proposed by the expert consensus panel (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/11\">",
"     11",
"    </a>",
"    ]. Prevention and treatment of TLS according to estimated risk of TLS are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link\">",
"     \"Tumor lysis syndrome: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21709828\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis and the release of large amounts of potassium, phosphate, and uric acid into the systemic circulation. Deposition of uric acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium phosphate crystals in the renal tubules can result in acute renal failure, which is usually anuric. (See",
"      <a class=\"local\" href=\"#H491545\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory TLS (TLS) is defined as any two or more abnormal serum values as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef59424 \" href=\"UTD.htm?19/28/19915\">",
"       table 1",
"      </a>",
"      ), and present within three days before or seven days after instituting chemotherapy in the setting of adequate hydration (with or without alkalinization) and use of a hypouricemic agent.",
"     </li>",
"     <li>",
"      Clinical TLS is defined as laboratory TLS plus one or more of the following that was not directly or probably attributable to a therapeutic agent: increased serum creatinine concentration (&ge;1.5 times the ULN), cardiac",
"      <span class=\"nowrap\">",
"       arrhythmia/sudden",
"      </span>",
"      death, or a seizure. A grading system for TLS based upon the severity of clinical TLS is presented in the table (",
"      <a class=\"graphic graphic_table graphicRef72208 \" href=\"UTD.htm?20/59/21436\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      TLS is observed most frequently in patients with high-grade lymphomas (particularly the Burkitt subtype) and mature B-cell acute lymphoblastic leukemia following the initiation of cytotoxic therapy, although it may also occur spontaneously",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in other tumor types with a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy. However, with the development of effective targeted therapy, TLS is now being reported in cancers that previously were only rarely associated with this complication, eg, colon cancer and chronic myeloid leukemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk stratification based upon tumor-related and patient-related factors can permit an assessment of the risk of TLS which may assist in selecting therapy (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 4",
"      </a>",
"      ). A simplified algorithmic approach to risk stratification for TLS is presented in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef63724 \" href=\"UTD.htm?23/2/23592\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19481/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/1\">",
"      Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/2\">",
"      van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/3\">",
"      Boles JM, Dutel JL, Briere J, et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984; 53:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/4\">",
"      Kanfer A, Richet G, Roland J, Chatelet F. Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma. Br Med J 1979; 1:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/5\">",
"      Seegmiller JE. Xanthine stone formation. Am J Med 1968; 45:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/6\">",
"      Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/7\">",
"      DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/8\">",
"      Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981; 41:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/9\">",
"      LaRosa C, McMullen L, Bakdash S, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007; 22:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/10\">",
"      Pais VM Jr, Lowe G, Lallas CD, et al. Xanthine urolithiasis. Urology 2006; 67:1084.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/11\">",
"      Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.",
"     </a>",
"    </li>",
"    <li>",
"     Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/13\">",
"      Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127:3.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/15\">",
"      Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/16\">",
"      Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/17\">",
"      W&ouml;ssmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/18\">",
"      Montesinos P, Lorenzo I, Mart&iacute;n G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/19\">",
"      Baeksgaard L, S&oslash;rensen JB. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature. Cancer Chemother Pharmacol 2003; 51:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/20\">",
"      Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/21\">",
"      Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/22\">",
"      Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/23\">",
"      Jabr FI. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol 2005; 82:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/24\">",
"      Linck D, Basara N, Tran V, et al. Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant 2003; 31:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/25\">",
"      Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/26\">",
"      Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol 2003; 72:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/27\">",
"      Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999; 105:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/28\">",
"      Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol 2008; 87:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/29\">",
"      Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006; 7:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/30\">",
"      Malik IA, Abubakar S, Alam F, Khan A. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J 1994; 87:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/31\">",
"      Tiley C, Grimwade D, Findlay M, et al. Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia. Leuk Lymphoma 1992; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/32\">",
"      Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther 2009; 34:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/33\">",
"      Yamazaki H, Hanada M, Horiki M, et al. Acute tumor lysis syndrome caused by palliative radiotherapy in patients with diffuse large B-cell lymphoma. Radiat Med 2004; 22:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/34\">",
"      Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006; 18:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/35\">",
"      Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997; 103:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/36\">",
"      Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 1994; 17:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/37\">",
"      Rostom AY, El-Hussainy G, Kandil A, Allam A. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol 2000; 11:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/38\">",
"      Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer 2001; 9:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/39\">",
"      Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol 1993; 44:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/40\">",
"      Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 1993; 21:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/41\">",
"      Chan JK, Lin SS, McMeekin DS, Berman ML. Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer. J Clin Oncol 2005; 23:6794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/42\">",
"      Shamseddine AI, Khalil AM, Wehbeh MH. Acute tumor lysis syndrome with squamous cell carcinoma of the vulva. Gynecol Oncol 1993; 51:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/43\">",
"      Oztop I, Demirkan B, Yaren A, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori 2004; 90:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/44\">",
"      Lin CJ, Lim KH, Cheng YC, et al. Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma. Med Oncol 2007; 24:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/45\">",
"      Pinder EM, Atwal GS, Ayantunde AA, et al. Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571). Sarcoma 2007; 2007:82012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/46\">",
"      Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol 1994; 47:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/47\">",
"      Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol 2004; 79:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/48\">",
"      Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol 1995; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/49\">",
"      Bertrand Y, Mechinaud F, Brethon B, et al. SFCE (Soci&eacute;t&eacute; Fran&ccedil;aise de Lutte contre les Cancers et Leuc&eacute;mies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. J Pediatr Hematol Oncol 2008; 30:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/50\">",
"      Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/51\">",
"      Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/52\">",
"      Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 2006; 47:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19481/abstract/53\">",
"      Truong TH, Beyene J, Hitzler J, et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer 2007; 110:1832.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1154 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E002DE631A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19481=[""].join("\n");
var outline_f19_1_19481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21709828\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H491545\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H491572\">",
"      Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H491579\">",
"      Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H491586\">",
"      Xanthinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H491877\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cairo-Bishop definition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Spontaneous TLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21709492\">",
"      High-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21709499\">",
"      Intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21709506\">",
"      Low-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk stratification in acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21709828\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1154|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/2/23592\" title=\"algorithm 1\">",
"      Algorithm for risk assessment TLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1154|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/22/21869\" title=\"figure 1\">",
"      Uric acid pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1154|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/50/11040\" title=\"picture 1\">",
"      Uric acid crystals in the urine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/28/19915\" title=\"table 1\">",
"      Cairo-Bishop define TLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/59/21436\" title=\"table 2\">",
"      Cairo-Bishop TLS grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/24/1421\" title=\"table 3\">",
"      Malignancies highrisk TLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22701\" title=\"table 4\">",
"      TLS risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/55/16252\" title=\"table 5\">",
"      Prog fac CTLS AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=related_link\">",
"      Overview of the causes and treatment of hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_1_19482="Diagnosis of asthma in adolescents and adults";
var content_f19_1_19482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of asthma in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Christopher H Fanta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/1/19482/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/1/19482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"classic\" signs and symptoms of asthma are intermittent dyspnea, cough, and wheezing. Although familiar to most clinicians, these symptoms are nonspecific, making it sometimes difficult to distinguish asthma from other respiratory diseases. The diagnosis of asthma requires the history or presence of respiratory symptoms consistent with asthma, combined with the demonstration of variable expiratory airflow obstruction.",
"   </p>",
"   <p>",
"    The tools used to diagnose asthma include history, physical examination, pulmonary function testing, and other laboratory evaluations. This topic review describes these tools, followed by several specific strategies for making the diagnosis of asthma in adolescents and adults. The information herein is consistent with \"The National Asthma Education and Prevention Program (NAEPP): Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma -- Full Report 2007\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of asthma in children and older adults and an overview of asthma management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=see_link\">",
"     \"Diagnosis and management of asthma in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma has defied a precise definition acceptable to all disciplines. Part of the problem relates to the lack of specificity of the symptoms. Pathologically, asthma may be described broadly as \"a chronic inflammatory disorder of the airways\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ]. However, this description omits the characteristic waxing and waning of airflow obstruction in asthma. A more useful definition would combine the central roles of inflammation and bronchial hyperresponsiveness with the characteristic clinical symptoms. As an example, asthma may be defined as &ldquo;a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. The interaction of these features of asthma determines the clinical manifestations and severity of asthma and the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The latter definition of asthma has features that overlap with the description of chronic obstructive pulmonary disease (COPD). Besides historic features (eg, onset in middle age and older, history of cigarette smoking), the characteristic that best distinguishes COPD from asthma is the degree of reversibility of airflow obstruction. In most instances the airflow obstruction of asthma is largely or completely reversible, while that of COPD is irreversible or incompletely reversible. (See",
"    <a class=\"local\" href=\"#H20489068\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Reactive airways disease\" is a nonspecific term that was used in the past to describe some features of asthma; however, it is now avoided in reference to adolescents and adults by most asthma specialists due to the lack of a clear definition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/2\">",
"     2",
"    </a>",
"    ]. \"Reactive airways dysfunction syndrome (RADS)\" refers to the nonimmunologic provocation of prolonged bronchial hyperresponsiveness and airflow obstruction by exposure to an inhaled irritant or noxious gas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma may develop at any age, although new-onset asthma is less frequent in older adults compared to other age groups. Clinicians treating adolescents and adults will often encounter patients whose diagnosis of asthma was made years earlier. Asthma is diagnosed before the age of seven years in approximately 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/3\">",
"     3",
"    </a>",
"    ]. Many adolescents experience a remission of childhood asthma symptoms around the time of puberty, with potential recurrence years later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pattern of respiratory symptoms that occur with exposure to triggers (eg, allergen, exercise, viral infection) and resolve with trigger avoidance or asthma medication is typical of asthma. Some patients will report all three of the classic symptoms of asthma, while others may report only one or two:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wheeze (high-pitched whistling sound, usually upon exhalation)",
"     </li>",
"     <li>",
"      Cough (often worse at night)",
"     </li>",
"     <li>",
"      Shortness of breath or difficulty breathing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    \"Wheezing\" does not have a standard meaning for patients and may be used by those without a medical background to describe a variety of sounds, including upper airway noises from the nose or throat. Cough may be dry or productive of clear mucoid or pale yellow sputum (made discolored by the presence of eosinophils). Asthma is a common cause of unexplained chronic cough. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients describe chest tightness, a band-like constriction, or the sensation of a heavy weight on the chest. In contrast, sharp chest pain is rarely used to describe the sensation of asthma.",
"   </p>",
"   <p>",
"    Because the symptoms of asthma are also seen in several other respiratory diseases, it is difficult to be certain of the diagnosis of asthma based upon history alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, certain historical features heighten the probability of asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic symptoms &ndash; Asthmatic symptoms characteristically come and go, with a time course of hours to days, resolving spontaneously with removal from the triggering stimulus or in response to anti-asthmatic medications. Patients with asthma may remain asymptomatic for long periods of time. Report of symptoms that occur or worsen at night is a feature of asthma.",
"     </li>",
"     <li>",
"      Characteristic triggers &ndash; Respiratory symptoms triggered by exercise, cold air, and exposure to allergens are suggestive of asthma. A list of questions that can help elicit a history of asthma triggers is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Exercise-triggered symptoms typically develop 5 to 15 minutes after a brief exertion or about 15 minutes into prolonged exercise and resolve with rest over approximately 30 to 60 minutes. This time-course is distinct from simple exertional dyspnea, which typically begins shortly after the onset of exertion and abates within five minutes of stopping exercise. In asthma, exercise-induced symptoms occur more commonly and are more intense when the inhaled air is cold. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link&amp;anchor=H4#H4\">",
"       \"Exercise-induced bronchoconstriction\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Allergens that commonly trigger asthmatic symptoms include dust mites, molds, furry animals, cockroaches, and pollens (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"       1",
"      </a>",
"      ]. The acute onset of lower respiratory tract symptoms reliably precipitated by exposure to a cat or dog is virtually pathognomic of asthma. Other irritant-type exposures (eg, cigarette smoke, strong fumes, changes in weather, airborne chemicals or dusts) are non-specific and do not favor a diagnosis of asthma over other respiratory diseases. Viral infections are common triggers for asthma, although they can trigger exacerbations in other chronic respiratory conditions as well. Unique to asthma is the onset of cough, wheeze,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest tightness 30 to 120 minutes following ingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or any cyclooxygenase-1 inhibitor (referred to as &ldquo;aspirin-sensitive asthma&rdquo; or &ldquo;aspirin-exacerbated respiratory disease&rdquo;), but this sensitivity occurs in only a small minority (3 to 5 percent) of asthmatic patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Personal or family history of atopy &ndash; A strong family history of asthma and allergies or a personal history of atopic diseases (eg, atopic dermatitis, seasonal allergic rhinitis and conjunctivitis) favors a diagnosis of asthma in a patient with suggestive symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H7#H7\">",
"       \"Risk factors for asthma\", section on 'Atopy and allergens'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=see_link\">",
"       \"Genetics of asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of asthmatic symptoms as a child &ndash; As previously mentioned, recollection of childhood symptoms of chronic cough, nocturnal cough in the absence of respiratory infections, or a childhood diagnosis of \"recurrent bronchitis\" or \"wheezy bronchitis\" favors asthma, but is also consistent with bronchiectasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain historic features lessen the prior probability of asthma. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of improvement following anti-asthmatic medications &ndash; Patients who have tried an inhaled bronchodilator and obtained no relief of their symptoms are less likely to have asthma. Similarly, lack of dramatic improvement with a course of oral glucocorticoids suggests a diagnosis other than asthma. (See",
"      <a class=\"local\" href=\"#H20489068\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Onset of symptoms after age 50 &ndash; In middle-aged and older patients, other respiratory and cardiovascular diseases with overlapping manifestations become the more likely explanation for these symptoms although the new onset of asthma remains a possibility. The evaluation of asthma in older adults is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=see_link\">",
"       \"Diagnosis and management of asthma in older adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concomitant symptoms such as chest pain, lightheadedness, syncope, or palpitations suggest an alternate diagnosis such as pulmonary vascular disease, cardiomyopathy, early coronary artery disease, or pericardial disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"       \"Evaluation of the adult with dyspnea in the emergency department\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"       \"Approach to the adult patient with syncope in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of cigarette smoking &ndash; In patients with more than 20 pack-years of cigarette smoking, the likely etiology of cough, wheeze, and shortness of breath shifts away from asthma toward chronic obstructive pulmonary disease, although the two diseases can co-exist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread, high-pitched, musical wheezes are a characteristic feature of asthma, although wheezes are not specific for asthma and are usually absent between asthma exacerbations. Wheezes are heard most commonly on expiration, but can also occur during inspiration. Asthmatic wheezing usually involves sounds of multiple different pitches, starting and stopping at various points in the respiratory cycle and varying in tone and duration over time. It is different from the monophasic wheezing of a local bronchial narrowing (eg, due to an aspirated foreign body or bronchogenic cancer), which has single pitch and repeatedly begins and ends at the same point in each respiratory cycle.",
"   </p>",
"   <p>",
"    Expiratory noises transmitted from the upper airway (eg, larynx, pharynx) can mimic wheezing and are often described as wheezing by patients. However, these upper airway noises are typically loudest over the neck and greatly diminished over the chest in contrast to true wheezes that are typically louder over the chest. Patients may be able to identify respiratory noises as inspiratory rather than expiratory. Clinicians can usually distinguish the low-pitched wheezes (also called &ldquo;rhonchi&rdquo;) that clear with cough, a sign of increased airway secretions as may be seen in bronchitis or bronchiectasis, from the typical high-pitched expiratory wheezes of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=see_link\">",
"     \"Diagnosis of wheezing illnesses other than asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical findings that suggest",
"    <strong>",
"     severe",
"    </strong>",
"    airflow obstruction in asthma include tachypnea, tachycardia, prolonged expiratory phase of respiration (decreased I:E ratio), and a seated position with use of extended arms to support the upper chest (\"tripod position\"). Use of the accessory muscles of breathing (eg, sternocleidomastoid) during inspiration and a pulsus paradoxus (greater than 12 mmHg fall in systolic blood pressure during inspiration) are usually found only during severe asthmatic attacks. However, these signs are insensitive manifestations of severe airflow obstruction; their absence does not exclude the possibility of a severe asthmatic attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Clinical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Importantly, the presence or absence of wheezing on physical examination is a poor predictor of the severity of airflow obstruction in asthma. Wheezing may be heard in patients with mild, moderate, or severe airway narrowing, while widespread airway narrowing may be present in individuals without wheezing. Thus, the presence of wheezing alerts one to the likely presence of airway narrowing, but not its severity.",
"   </p>",
"   <p>",
"    Extrapulmonary physical findings in patients with asthma that can provide evidence for or against a diagnosis of asthma include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pale, swollen lining on examination of the nasal cavities with an otoscope suggests associated allergic rhinitis, a common condition among patients with allergic asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nasal polyps, which appear as glistening, gray, mucoid masses within the nasal cavities, should prompt questioning about concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      sensitivity, anosmia, and chronic sinusitis (",
"      <a class=\"graphic graphic_figure graphicRef50105 \" href=\"UTD.htm?26/4/26688\">",
"       figure 1",
"      </a>",
"      ). Since aspirin-exacerbated respiratory disease (asthma, nasal polyps, and aspirin sensitivity) is uncommon in childhood, the finding of nasal polyps in an adolescent with lower respiratory tract symptoms should lead to consideration of alternative diagnoses, specifically cystic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atopic dermatitis with typical lichenified plaques in a flexural distribution, especially of the antecubital and popliteal fossae, volar aspect of the wrists, ankles, and neck (",
"      <a class=\"graphic graphic_picture graphicRef64525 \" href=\"UTD.htm?23/31/24051\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef55375 \" href=\"UTD.htm?41/10/42147\">",
"       picture 2",
"      </a>",
"      ), is a risk factor for later asthma. About a third of patients with atopic dermatitis develop asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H7#H7\">",
"       \"Risk factors for asthma\", section on 'Atopy and allergens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clubbing is not a feature of asthma; its presence should direct the clinician toward alternative diagnoses such as interstitial lung disease, lung cancer, and diffuse bronchiectasis, including cystic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24992570\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with suspected asthma is predominantly focused on pulmonary function testing. Other laboratory studies, including chest radiography, blood tests, and tests for allergy, are useful in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests of airflow limitation are critical tools in the diagnosis of asthma. A detailed discussion of a wider range of pulmonary function tests used in the diagnosis of asthma and other causes of shortness of breath is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry, in which a maximal inhalation is followed by a rapid and forceful complete exhalation into a spirometer, includes measurement of forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) and forced vital capacity (FVC) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/7\">",
"     7",
"    </a>",
"    ]. These measurements provide information that is essential to the diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ]. We obtain baseline spirometry in virtually all patients with a suspected diagnosis of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of spirometry can be used to determine the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Determine whether baseline airflow limitation (obstruction) is present (reduced",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio)",
"     </li>",
"     <li>",
"      Assess the reversibility of the obstructive abnormality if the testing is repeated after administration of a bronchodilator",
"     </li>",
"     <li>",
"      Characterize the severity of airflow limitation",
"     </li>",
"     <li>",
"      For patients with normal airflow (normal",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio), identify a restrictive pattern as an alternate explanation for dyspnea (eg, FVC &lt;80 percent predicted)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An obstructive pattern on spirometry is identified numerically by a reduction in the ratio of FEV",
"    <sub>",
"     1",
"    </sub>",
"    to FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/8\">",
"     8",
"    </a>",
"    ]. When",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    is reduced below normal (less than 0.70 or less than the lower limit of normal [LLN], which is the cut-off at the fifth percentile of the confidence interval provided electronically by modern computerized spirometers), airflow obstruction is present. When the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio is normal or increased, there is no expiratory airflow obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Having identified the presence of airflow obstruction by a reduction in",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC,",
"    </span>",
"    the severity of airflow obstruction is then categorized by the degree of reduction of the FEV",
"    <sub>",
"     1",
"    </sub>",
"    below normal. The severity of airflow obstruction based on spirometry is graded as borderline, mild, moderate, and severe as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 2",
"    </a>",
"    ), although other grading systems can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These categories are used for pulmonary function interpretation and are NOT the same as categories used by the National Asthma Education and Prevention Program (NAEPP) guidelines to stage asthma severity (",
"    <a class=\"graphic graphic_table graphicRef71425 \" href=\"UTD.htm?22/7/22653\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An obstructive pattern can also be identified visually by inspection of the shape of the expiratory flow-volume curve that is often provided by modern spirometry equipment. A scooped, concave appearance to the expiratory portion of the flow-volume loop signifies diffuse intrathoracic airflow obstruction, typical of asthma and many other obstructive lung diseases (",
"    <a class=\"graphic graphic_figure graphicRef58092 \" href=\"UTD.htm?35/47/36605\">",
"     figure 3",
"    </a>",
"    ). Inspection of the inspiratory and expiratory portions of the flow-volume loop can also be useful in identifying the characteristic patterns seen in upper airway obstruction (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Flow-volume loop'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bronchodilator response",
"    </span>",
"    &nbsp;&mdash;&nbsp;We assess bronchodilator reversibility in almost all adult and adolescent patients with airflow limitation on their baseline spirometry, as recommended by the NAEPP guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute reversibility of airflow obstruction is tested by administering 2 to 4 puffs of a quick-acting bronchodilator (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ), preferably with a chamber device, and repeating spirometry 10 to 15 minutes later. An increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 12 percent or more, accompanied by an absolute increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of at least 200 mL, can be attributed to bronchodilator responsiveness with 95 percent certainty.",
"   </p>",
"   <p>",
"    The presence of a bronchodilator response, in isolation, is not sufficient to make the diagnosis of asthma, however. Bronchodilator responsiveness may be seen with other conditions, such as COPD, bronchiectasis, cystic fibrosis, and bronchiolitis. Asthma is typically distinguished from these other conditions by the capacity for a \"large\" increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    . The definition of a large bronchodilator response is not standardized; investigators generally classify a large response as at least 15 to 20 percent. However, there is no precise cutoff value that defines an \"asthmatic\" bronchodilator response.",
"   </p>",
"   <p>",
"    Occasionally, patients with asthma will have airflow obstruction on spirometry but fail to exhibit a 12 percent or greater increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    following bronchodilator (a \"false negative\" response). Reasons for false negatives include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate inhalation of the bronchodilator due to problems using the metered-dose inhaler correctly",
"     </li>",
"     <li>",
"      Recent use of a quick-acting bronchodilator or other anti-asthmatic medications (eg, long-acting bronchodilators), resulting in near-maximal bronchodilation prior to testing",
"     </li>",
"     <li>",
"      Minimal airflow obstruction at the time of testing (FEV",
"      <sub>",
"       1",
"      </sub>",
"      already close to 100 percent)",
"     </li>",
"     <li>",
"      In some patients with asthma, the presence of irreversible airways obstruction due to chronic airways inflammation or scarring (also known as \"airway remodeling\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bronchoprovocation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoprovocation challenge testing is available in most pulmonary function testing laboratories and is a useful tool for diagnosing asthma in patients with normal baseline airflow. We typically obtain bronchoprovocation testing in patients with an atypical presentation (eg, normal baseline spirometry, no variability in airflow limitation with serial spirometry or peak flow) or isolated symptoms of asthma, especially cough. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A provocative stimulus (eg, inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , exercise, or hyperventilation of cold, dry air) is used to stimulate bronchoconstriction. People with asthma are more sensitive (hyperresponsive) to such stimuli than those without asthma (",
"    <a class=\"graphic graphic_figure graphicRef82365 \" href=\"UTD.htm?41/63/43005\">",
"     figure 5",
"    </a>",
"    ). When paradoxical vocal cord motion is being considered in the differential, an inspiratory and expiratory flow volume loop and sometimes also direct laryngoscopy are performed during bronchoprovocation testing to identify an upper airway response mimicking asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link&amp;anchor=H12#H12\">",
"     \"Paradoxical vocal cord motion\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technical aspects of performing this type of testing, interpreting the results, and identifying the causes of false positive and false negative results are presented separately. A positive test (indicating bronchial hyperresponsiveness) is not entirely specific for asthma. Using a cut point of 8",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    or less to indicate the presence of hyperresponsiveness, as many as 5 percent of the normal population and a greater percentage of non-asthmatic persons with rhinitis will exhibit positive results. However, false negative results are uncommon, and a negative test (no significant decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at the highest dose of methacholine administered) reliably excludes the diagnosis of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H9#H9\">",
"     \"Bronchoprovocation testing\", section on 'Pharmacologic challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other specialized provocation testing can be used when further evaluation of the role of a specific precipitating factor is needed. Typical examples include measuring lung function before and after exercise when a diagnosis of exercise-induced bronchoconstriction related to asthma is suspected and evaluation of possible occupational asthma by FEV",
"    <sub>",
"     1",
"    </sub>",
"    or PEF measurements made before and after the work shift. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H12#H12\">",
"     \"Bronchoprovocation testing\", section on 'Exercise challenge'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957546\">",
"    <span class=\"h3\">",
"     Peak expiratory flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak expiratory flow (PEF) is measured during a brief, forceful exhalation, using a simple and inexpensive device (approximately $35). We typically use PEF measurements to monitor patients with a known diagnosis of asthma or to assess the role of a particular occupational exposure or trigger, rather than as a tool for the primary diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to spirometry, applying quality control to peak flow measurements is difficult because of the lack of graphic display to ensure maximal patient effort and appropriate technique.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      &ndash; The PEF maneuver can be performed sitting or standing. Proper technique involves taking a maximally large breath in, putting the peak flow meter quickly to the mouth, sealing the lips around the mouthpiece, and blowing out as hard and fast as possible into the meter. For PEF, the effort does not need to be sustained beyond one to two seconds. The maneuver is performed three times and the highest of the three measurements is recorded (",
"      <a class=\"graphic graphic_table graphicRef53856 \" href=\"UTD.htm?21/51/22331\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79373 \" href=\"UTD.htm?14/21/14686\">",
"       figure 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"       \"Peak expiratory flow rate monitoring in asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Normal values",
"      </strong>",
"      &ndash; Average normal values for men and women are based upon height and age (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?14/9/14481?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef57257 graphicRef62839 \" href=\"UTD.htm?2/12/2254\">",
"       table 4A-B",
"      </a>",
"      ). Average normal values for adolescents are based upon height (",
"      <a class=\"graphic graphic_table graphicRef64420 \" href=\"UTD.htm?1/12/1229\">",
"       table 5",
"      </a>",
"      ). The range of normal values around the mean is up to 80 to 100",
"      <span class=\"nowrap\">",
"       L/min.",
"      </span>",
"      &nbsp;",
"      <br/>",
"     </li>",
"     <li>",
"      <strong>",
"       Interpretation of PEF &ndash;",
"      </strong>",
"      A single peak flow determination made in the doctor's office at the time that a patient is experiencing respiratory symptoms, if reduced from the normal predicted value, is suggestive of asthma. However, it is not diagnostic because a reduced peak flow is not specific for airflow obstruction and can be seen with other pulmonary processes. On the other hand, a reduced peak flow that improves by more than 20 percent approximately 10 to 20 minutes after administration of a quick-acting bronchodilator (eg, inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ) provides supportive evidence favoring the diagnosis of asthma.",
"      <br/>",
"      <br/>",
"      PEF measurements may vary as much as 15 to 20 percent from one measurement to the next in patients with asthma but without symptoms and in individuals without asthma. PEF results that vary little over time (less than 20 percent of the maximal value) argue against the diagnosis of asthma, particularly if reported symptoms are associated with unchanging peak flow measurements. In contrast, peak flow values that repeatedly fall by more than 20 percent when symptoms are present and return to baseline as symptoms resolve are consistent with asthma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Limitations of PEF",
"      </strong>",
"      &ndash; PEF measurement has several shortcomings as a diagnostic tool for asthma, including [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1,7,8,10-13\">",
"       1,7,8,10-13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild airflow obstruction may be present on spirometry when the peak flow is within the normal range.",
"     </li>",
"     <li>",
"      Reduced peak flow measurements may be seen in both obstructive and restrictive diseases. Spirometry and sometimes measurement of lung volumes are necessary to distinguish the two.",
"     </li>",
"     <li>",
"      Peak flow measurements are not sufficient to distinguish upper airway obstruction (eg, vocal cord dysfunction) from asthma. Spirometry with a flow volume loop is needed for evaluation of upper airway obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of pulmonary function testing in adults\", section on 'Flow-volume loop'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The validity of PEF measurements depends entirely upon patient effort and technique. Errors in performing the test frequently lead to underestimation of true values, and occasionally to overestimation.",
"     </li>",
"     <li>",
"      Home PEF monitoring is unsupervised. Patients may produce higher values in the clinician&rsquo;s office with appropriate coaching to ensure a maximal effort.",
"     </li>",
"     <li>",
"      Peak flow meters cannot be routinely calibrated, unlike spirometers. Thus, results and percent predicted values will vary somewhat between different instruments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Exhaled nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of nitric oxide in a patient's exhaled breath (eNO) is being investigated as a method that might aid in the diagnosis of asthma, but is not widely available. The test is based on the observation that the eosinophilic airway inflammation associated with asthma leads to up-regulation of nitric oxide synthase in the respiratory mucosa, which in turn generates increased amounts of nitric oxide in the exhaled breath. Carefully calibrated equipment is designed to differentiate the concentration (in parts per billion) of nitric oxide in the exhaled breath of persons with asthma from the low levels of nitric oxide present in the exhaled breath of normal individuals. Further studies are required to assess the validity of exhaled nitric oxide as a diagnostic test for asthma, particularly among persons with other, potentially confounding respiratory diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"     \"Exhaled nitric oxide analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;No blood tests are available that assess the presence or absence of asthma or gauge its severity. However, a complete blood count (CBC) with differential white blood cell analysis to screen for eosinophilia or significant anemia may be helpful in certain cases. We typically obtain a CBC and differential when asthma symptoms are severe, the patient presents to the hospital with an exacerbation, nasal polyposis is present, the chest radiograph is abnormal (eg, suggestive of eosinophilic pneumonia or Churg Strauss syndrome), or a parasitic infection is suspected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated eosinophil percentage by automated cell sorter is best confirmed by manual differential (to exclude erroneous classification of neutrophils as eosinophils). Markedly elevated eosinophil percentages (&gt;15 percent) or counts (&gt;1500",
"      <span class=\"nowrap\">",
"       eosinophils/microL)",
"      </span>",
"      may be due to allergic asthma, but should prompt consideration of alternative diagnoses, including parasitic infections (eg, Strongyloides), drug reactions, and syndromes of pulmonary infiltrates with eosinophilia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"       \"Causes of pulmonary eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Significant anemia can cause dyspnea that is unresponsive to asthma therapies and would require further evaluation to determine the causative process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the lifelong non-smoker with persistent and irreversible airflow obstruction, a one-time measurement of the serum alpha-1 antitrypsin level is recommended to exclude emphysema due to homozygous alpha-1 antitrypsin deficiency, which is in the differential of chronic and largely irreversible airflow limitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tests for allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy tests are not useful for the diagnosis of asthma, but they can be helpful to confirm sensitivity to suspected allergic triggers of respiratory symptoms and to guide on-going management of asthma. We usually perform allergy testing in selected patients with a history of symptoms that occur upon exposure to particular aeroallergen(s) (",
"    <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"     table 1",
"    </a>",
"    ), ongoing exposure to inhalant allergens (eg, animal dander, dust mite),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of moderate-to-severe asthma symptoms. In addition to the peripheral blood eosinophil count mentioned above, the main tests for allergy are the nonspecific total serum immunoglobulin E (IgE) level and the tests for specific allergic sensitization, which include blood testing for specific IgE antibody to inhalant allergens and skin testing with extracts of inhalant allergens.",
"   </p>",
"   <p>",
"    Measurement of total serum immunoglobulin E (IgE) levels is indicated in patients with moderate-to-severe persistent asthma when considering treatment with anti-IgE monoclonal antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) or when allergic bronchopulmonary aspergillosis is suspected on the basis of eosinophilia, a positive skin test to aspergillus, or radiographic evidence of mucus plugging or central bronchiectasis. An elevated total IgE level may occur in the absence of asthma (eg, in allergic rhinitis or eczema), and allergic asthma may be present in the absence of an elevated total IgE level, which may not fully reflect the levels of mast cell-bound IgE in airway tissue. Very high total IgE levels (&gt;1000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    are typically found in persons with allergic bronchopulmonary aspergillosis, certain parasitic infections, and sometimes eczema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H13745149#H13745149\">",
"     \"The biology of IgE\", section on 'Increased total IgE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allergic sensitivity to specific allergens in the environment can be assessed using either of two methods: allergy skin tests and blood tests for allergen-specific IgE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood tests for allergen-specific IgE most commonly utilize enzyme-linked immunosorbent assays (ELISA) to measure minute quantities of IgE antibody specifically directed at particular antigens (as opposed to the total serum IgE discussed above). Based on the aeroallergens in the patient&rsquo;s geographic location and household, a panel of immunoassays is ordered. Aeroallergens (eg, house dust mite antigen, cat and dog danders, cockroach antigen, pollens, and mold spores) are the types of allergens most commonly implicated in asthma. Food allergens rarely cause isolated asthmatic symptoms. By asking relatively few specific questions, clinicians can often elicit a potential relationship between allergen exposure and asthmatic symptoms that will guide the choice of which antigens to assess by immunoassay (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 1",
"      </a>",
"      ). When ordering these blood tests, one can select specific antigens for testing or choose among pre-grouped panels of antigens. The technique and accuracy of immunoassays are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of in vitro allergy tests\", section on 'Immunoassays'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergy skin tests are performed to a panel of indoor and outdoor aeroallergens. The negative predictive value of skin testing (using prick and intradermal techniques) is very high, such that skin testing can exclude allergy with relative certainty. Skin testing should be performed by a trained allergy technician and interpreted by an allergy specialist. The indications, contraindications, technique, and interpretation of allergy skin tests are presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages of in vitro testing over skin testing are that no trained technician is needed to apply the test, antihistamines and other medications do not interfere with the results, and there is no risk of adverse reactions (eg, inducing asthmatic reactions or anaphylaxis). The disadvantages are the greater cost and somewhat lesser sensitivity of immunoassays compared with skin testing and lack of the immediate and often powerful visual feedback for the patient that occurs with a positive skin test reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24992678\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph is almost always normal in patients with asthma. However, many clinicians, including ourselves, obtain a chest radiograph for new-onset moderate-to-severe asthma in adults over age 40 to exclude the occasional alternative diagnosis that may mimic asthma (eg, the mediastinal mass with tracheal compression or heart failure). The cost-effectiveness of this approach has not been evaluated.",
"   </p>",
"   <p>",
"    In contrast, chest radiographs are routinely recommended when evaluating severe or \"difficult-to-control\" asthma and when co-morbid conditions (eg, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, and atelectasis due to mucus plugging) are suspected based on history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other laboratory data.",
"   </p>",
"   <p>",
"    In addition, chest radiography is indicated in patients presenting with features that are atypical for asthma, including any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Chronic purulent sputum production",
"     </li>",
"     <li>",
"      Persistently localized wheezing",
"     </li>",
"     <li>",
"      Hemoptysis",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Clubbing",
"     </li>",
"     <li>",
"      Inspiratory crackles",
"     </li>",
"     <li>",
"      Significant hypoxemia (eg, pulse oxygen saturation less than approximately 94 percent) in the absence of an acute asthmatic attack",
"     </li>",
"     <li>",
"      Moderate or severe airflow obstruction that does not reverse with bronchodilators",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) scanning is performed to clarify abnormalities seen on conventional chest radiography or when other processes are suspected, such as bronchiectasis, bronchiolitis obliterans (eg, largely irreversible airflow limitation, reduced diffusing capacity), and vascular anomalies compromising central airways (eg, right sided aortic arch and aberrant left subclavian artery). (See",
"    <a class=\"local\" href=\"#H20489068\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link&amp;anchor=H7#H7\">",
"     \"Vascular rings\", section on 'R aortic arch with aberrant L subclavian artery and L ductus arteriosus/ligamentum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of intermittent symptoms typical of asthma plus the finding on physical examination of characteristic musical wheezing (present in association with symptoms and absent when symptoms resolve) strongly point to a diagnosis of asthma. Confirmation of the diagnosis of asthma is based on two key additional elements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The demonstration of variable expiratory airflow limitation, preferably by spirometry",
"     </li>",
"     <li>",
"      Exclusion of alternative diagnoses (see",
"      <a class=\"local\" href=\"#H20489068\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spirometry is the primary method for confirming variable airflow limitation; variability may be demonstrated by testing before and after bronchodilator, from one office visit to another, or before and after bronchoprovocation challenge. Use of pulmonary function testing in this manner helps to prevent both over- and under-diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pulmonary function testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The results of initial spirometry are used to guide the diagnostic approach, as described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Initial spirometry shows airflow limitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A symptom pattern suggestive of asthma AND airflow limitation on initial spirometry, which completely reverses to normal following bronchodilator, virtually clinch the diagnosis of asthma. Likewise, typical symptoms and a large reversibility of airflow obstruction on spirometry (increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    &gt;15 percent) generally confirm the diagnosis of asthma. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bronchodilator response'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, reversible airflow obstruction in the patient with chronic cough but without other chest symptoms or wheezing on examination would assist in making the correct diagnosis of asthma. On the other hand, absence of or incomplete reversibility does not necessarily exclude asthma, as the airflow limitation can be caused by concomitant airway inflammation that will only reverse with anti-inflammatory medication (eg, inhaled or oral glucocorticoids) or removal from exposure to an aeroallergen. However, incomplete or absent reversibility should raise the possibility of an alternate diagnosis. (See",
"    <a class=\"local\" href=\"#H20489068\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Initial spirometry is normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asthma often have normal lung function at the time of evaluation. For these patients, the following strategies are used to confirm the clinical diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat spirometry at subsequent office visits when the patient is symptomatic",
"     </li>",
"     <li>",
"      Patient-recorded serial measurements of PEF over time (eg, morning and evening, with symptoms and again after a therapeutic trial of bronchodilator) using a portable device",
"     </li>",
"     <li>",
"      Bronchoprovocation testing, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , or exercise challenge (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Bronchoprovocation testing'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Serial measurements of lung function over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;One useful strategy for diagnosing asthma in patients with normal lung function on initial spirometry is to ask the patient to use a portable hand-held device to measure forced expiratory volume in one second or PEF and record readings obtained twice a day for two weeks or with and without symptoms. The diagnosis of asthma is confirmed by a reliable series of recordings that document more than 20 percent variability in FEV",
"    <sub>",
"     1",
"    </sub>",
"    or PEF over time (especially when these reductions are associated with asthmatic symptoms). Individuals without asthma experience little variability (less than 20 percent) in their PEF, even when respiratory symptoms are present.",
"   </p>",
"   <p>",
"    Similar data collection can take place in the clinician's office by recording spirometry or PEF at each patient visit. This method is less dependent on the reliability of the patient independently making self-measurements, although multiple visits may be required.",
"   </p>",
"   <p>",
"    Serial patient-recorded measurements of FEV",
"    <sub>",
"     1",
"    </sub>",
"    (using a small, electronic, hand-held device) or PEF can be combined with a \"therapeutic trial\" of a bronchodilator [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/15\">",
"     15",
"    </a>",
"    ]. Significant decreases in PEF that reverse within minutes of use of an inhaled beta-adrenergic agonist typify asthma. In individuals without asthma, the increase in PEF following bronchodilator administration would be expected to be less than 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bronchoprovocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of airways hyperresponsiveness, a key feature of asthma, can be confirmed with bronchoprovocation testing, usually in the form of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    inhalation challenge. This diagnostic strategy is particularly useful for patients with atypical symptoms or an atypical response to medications. Given the test&rsquo;s high negative predictive value, it is especially useful when exclusion of a diagnosis of asthma is helpful in patient management. Bronchoprovocation testing is a relatively costly diagnostic strategy and relies on the expertise of sophisticated pulmonary function laboratories. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Bronchoprovocation testing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H4#H4\">",
"     \"Bronchoprovocation testing\", section on 'Diagnosis of asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    provocation challenge (eg, a 20 percent decrease in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at a methacholine concentration of 8",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or less) is diagnostic of airways hyperresponsiveness. While airways hyperresponsiveness is most commonly due to asthma, other diseases, such as COPD, cystic fibrosis, and allergic rhinitis, can cause a &ldquo;false positive&rdquo; methacholine challenge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H5623764#H5623764\">",
"     \"Bronchoprovocation testing\", section on 'Interpretation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis based on history and clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, the history and clinical course are strongly suggestive of asthma, and a treatment trial is initiated as part of the diagnostic process. The combination of a typical presentation (eg, repeated episodes of typical symptoms triggered by typical stimuli), musical wheezes on auscultation, and a prompt response to anti-asthma medication may be used to make a presumptive diagnosis, as might occur for new-onset asthma presenting in an acute care setting. However, we agree with the NAEPP guidelines that the clinical diagnosis of asthma should be validated with objective data, whenever possible. For patients with less typical or more persistent or refractory symptoms, formal spirometric data are essential to ensure that the correct diagnosis is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20489068\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough, wheeze, shortness of breath, and chest tightness, while characteristic of asthma, are also symptoms of a number of other respiratory diseases affecting both the upper and lower respiratory tracts. Some of these diseases can also result in airflow obstruction on spirometry. In addition, certain non-respiratory conditions (eg, heart failure, gastroesophageal reflux) mimic asthma symptoms, and several prominent conditions may co-exist with asthma and increase its severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20489413\">",
"    <span class=\"h2\">",
"     Conditions causing similar symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative diagnoses that may cause cough, wheeze, or shortness of breath include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wheeze",
"      </strong>",
"      ��� Wheezing may be generated by luminal narrowing anywhere along the respiratory tract, including nares, pharynx, glottis, trachea, and bronchi. Inspiratory upper airway sounds, including stridor, are usually distinguishable from asthma. Expiratory wheezes emanating from the upper airway (eg, vocal cord dysfunction syndrome) are often readily audible without a stethoscope but sound distant on auscultation of the lower chest. However, at times these upper airway sounds may be transmitted widely throughout the chest, making differentiation from asthma difficult. A focal, monophonic wheeze (eg, bronchogenic carcinoma or foreign body aspiration) should not be confused with asthma. The full spectrum of disorders that can cause wheezing is presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=see_link\">",
"       \"Diagnosis of wheezing illnesses other than asthma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cough",
"      </strong>",
"      ��� When persistent cough is the presenting complaint and lung function and chest radiograph are normal, the differential includes rhinitis or rhinosinusitis, gastroesophageal reflux disease (GERD), post-viral tussive syndrome, eosinophilic bronchitis, cough induced by angiotensin converting enzyme inhibitors, and infection with Bordetella pertussis (\"whooping cough\"). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"       \"Evaluation of subacute and chronic cough in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Chronic bronchitis with normal spirometry is another cause of chronic cough. A small portion of cigarette smokers have a chronic productive cough for three months in two successive years, but do not have airflow limitation on pulmonary function tests. Some treatments for asthma may improve their cough.",
"     </li>",
"     <li>",
"      <strong>",
"       Dyspnea",
"      </strong>",
"      ��� Dyspnea has a broad differential, but the common causes that are in the differential of asthma are COPD, heart failure, pulmonary embolism, and sarcoidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"       \"Approach to the patient with dyspnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"       \"Evaluation of the adult with dyspnea in the emergency department\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Obesity can cause a pattern of dyspnea that mimics asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/14\">",
"       14",
"      </a>",
"      ]. In a study of patients with an elevated body mass index (BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and a doctor diagnosis of asthma, formal testing for bronchial hyperresponsiveness was negative in 36 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/17\">",
"       17",
"      </a>",
"      ]. This observation underscores the need for a definitive initial diagnosis of asthma. Obesity can also add to the severity of dyspnea in patients with asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H22#H22\">",
"       \"Risk factors for asthma\", section on 'Obesity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with asthma-like symptoms, the diagnostic considerations vary in part by age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adolescents and young to middle-aged adults, the principal considerations include recurrent bouts of bronchitis, bronchiolitis, bronchiectasis, paradoxical vocal cord motion, pulmonary embolism, gastroesophageal reflux disease (GERD), recurrent aspiration, panic disorder, and sarcoidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"       \"Gastroesophageal reflux and asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In older-aged patients, especially cigarette smokers, the principal considerations include COPD and left-ventricular heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20489160\">",
"    <span class=\"h2\">",
"     Conditions producing obstructive patterns on spirometry",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COPD typically presents in patients with a substantial smoking history (eg, &gt;20 pack years). The symptoms of dyspnea on exertion and cough with or without sputum production can mimic adult-onset asthma. Variable airflow obstruction over time and an improvement on post-bronchodilator spirometry can be seen, similar to asthma, although the improvement in postbronchodilator spirometry is generally less pronounced in COPD and does not achieve normal values. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiectasis, a condition of abnormal widening of the bronchi due to airway wall injury associated with chronic or recurrent infection, shares many clinical features with asthma, including inflamed airways, obstruction to airflow, and exacerbations characterized by increased dyspnea and sputum production. Bronchiectasis is suspected on the basis of prominent symptoms of cough and chronic mucopurulent sputum production. The diagnosis is usually established clinically based on the characteristic cough and purulent sputum production and the presence of bronchial wall thickening and luminal dilatation on chest computed tomographic (CT) scans. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Constrictive bronchiolitis, also known as bronchiolitis obliterans, is characterized by submucosal and peribronchiolar fibrosis that causes concentric narrowing of the bronchiolar lumen. Constrictive bronchiolitis is most commonly seen following viral illness, inhalation injury, transplantation (eg, bone marrow, lung), or in the context of rheumatoid lung or inflammatory bowel disease (",
"      <a class=\"graphic graphic_table graphicRef58035 \" href=\"UTD.htm?9/57/10139\">",
"       table 6",
"      </a>",
"      ). Symptoms include progressive onset of cough and dyspnea associated with hypoxemia at rest or with exercise. Crackles may be present. Pulmonary function tests show a progressive and irreversible airflow limitation. Findings on CT scan may include centrilobular bronchial wall thickening, bronchiolar dilation, tree-in-bud nodularity, and a mosaic ground-glass attenuation pattern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H11#H11\">",
"       \"Bronchiolitis in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central airway obstruction can be caused by numerous benign and malignant processes and can mimic asthma with dyspnea on exertion that may progress to dyspnea with minimal activity. Monophonic wheezing or stridor may be present. Symptoms are minimally improved by inhaled bronchodilator, if at all. A high index of suspicion is needed as conventional chest radiographs are rarely diagnostic. Flow volume loops can show the characteristic changes of upper airway obstruction, frequently before abnormalities in the spirometric volumes are noted (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73686 \" href=\"UTD.htm?27/40/28302\">",
"       figure 7",
"      </a>",
"      ). A high resolution CT scan with three-dimensional airway reconstruction can be helpful. The gold standard for diagnosis is direct visualization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"       \"Flow-volume loops\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20489168\">",
"    <span class=\"h2\">",
"     Co-existent conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain illnesses commonly co-exist with asthma and may exacerbate its course. These illnesses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of severe asthma in adolescents and adults\", section on 'Comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic rhinitis is present in most patients with allergic asthma and in at least 50 percent of those with non-allergic asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/18\">",
"       18",
"      </a>",
"      ]. The frequency with which rhinitis and asthma co-exist has prompted formation of the \"integrated airway hypothesis,\" which proposes that the two conditions are essentially one disorder, involving both the upper and lower airways in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/1/19482/abstract/19\">",
"       19",
"      </a>",
"      ]. Post-nasal drip associated with any form of chronic rhinitis or sinusitis can also worsen asthma symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GERD can mimic or worsen asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"       \"Gastroesophageal reflux and asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity is in the differential of asthma and is also a frequent co-existent condition. Patients with obesity and mild asthma may perceive more severe dyspnea that would be anticipated on the basis of spirometry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H22#H22\">",
"       \"Risk factors for asthma\", section on 'Obesity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with an asthma specialist, either a pulmonologist or an allergist, is warranted when the diagnosis of asthma is uncertain, when the asthma is difficult-to-control, medication side effects are intolerable, or when a patient has frequent exacerbations. Pulmonologists may be most helpful if alternative pulmonary diseases are suspected or if further pulmonary testing or bronchoscopy may be needed. Referral to an allergist may be most helpful if allergic triggers need further evaluation or if concomitant nasal and ocular allergy symptoms are difficult-to-control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma may develop at any age, although the majority of people with asthma are diagnosed in childhood. The clinical history in an adult should include questions about the presence of symptoms earlier in life. Other historic clues that are highly suggestive of asthma include recurring, episodic symptoms, the presence of typical triggers (especially exercise, cold air, or allergen exposure), and personal or family history of allergic disease (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination may be normal in asthma. The presence of abnormal findings (such as wheezing) is suggestive of asthma, although not specific. Asthmatic wheezing is typically composed of multiple high-pitched sounds audible during expiration. Nasal examination should be included to check for the pale, swollen mucosa of associated allergic rhinitis or nasal polyps that raise the possibility of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -exacerbated respiratory disease (also known as aspirin-sensitive asthma). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pulmonary function tests most helpful in diagnosing asthma are spirometry pre and post bronchodilator, bronchoprovocation testing (usually with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ), and peak expiratory flow (PEF) monitoring. A reversible reduction in the forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) and the",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /forced",
"      </span>",
"      vital capacity (FVC) ratio on spirometry, heightened sensitivity to bronchoprovocation testing, and variability of &gt;20 percent in PEF are findings consistent with asthma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary function testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other laboratory studies are sometimes indicated to identify potential asthma triggers and exclude alternate diagnoses, including blood tests, skin testing for environmental allergies, and a chest radiograph. (See",
"      <a class=\"local\" href=\"#H24992570\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of asthma is based upon the presence or history of symptoms consistent with asthma (most commonly episodic cough, wheezing, or dyspnea provoked by typical triggers), combined with the demonstration of variable expiratory airflow obstruction. The strategies for using pulmonary function testing vary based on the results of baseline spirometry. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred approach to the diagnosis of asthma is the use of spirometry to identify reversible airflow obstruction. An obstructive pattern with an increase in FEV",
"      <sub>",
"       1",
"      </sub>",
"      of more than 12 percent from the baseline measurement, following administration of 2 to 4 puffs of a quick-acting bronchodilator, is suggestive of asthma, especially if post-bronchodilator spirometry is normal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Spirometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach is to obtain serial measurements of FEV",
"      <sub>",
"       1",
"      </sub>",
"      or PEF over time at home or in the office. Patients can track the results in a peak flow diary (",
"      <a class=\"graphic graphic_figure graphicRef79373 \" href=\"UTD.htm?14/21/14686\">",
"       figure 6",
"      </a>",
"      ). A variability of &gt;20 percent that corresponds to symptoms is strongly suggestive of asthma. PEF measurement can be combined with a therapeutic trial of inhaled bronchodilator. (See",
"      <a class=\"local\" href=\"#H2957546\">",
"       'Peak expiratory flow'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Serial measurements of lung function over time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoprovocation testing, such as with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , or exercise challenge, is typically used only when the baseline spirometry is normal. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bronchoprovocation testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"       \"Bronchoprovocation testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For clinical settings in which neither spirometry nor peak flow measurement is available, a diagnosis of probable asthma can be made based upon history alone, provided the patient has typical symptoms that respond promptly and completely to therapy. History-based diagnosis is also appropriate for urgent care settings in patients who respond to asthma therapies as expected. Peak flow measurements are appropriate in these office-based and urgent care settings to supplement history and exam. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosis based on history and clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of asthma includes respiratory and non-respiratory conditions that may cause similar symptoms, wheezing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an obstructive pattern on spirometry. Evaluation should include assessment for conditions that may co-exist with asthma and worsen its severity. (See",
"      <a class=\"local\" href=\"#H20489068\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classification of asthma severity (",
"      <a class=\"graphic graphic_table graphicRef71425 \" href=\"UTD.htm?22/7/22653\">",
"       table 2",
"      </a>",
"      ) and a step-wise approach to asthma management are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"       \"An overview of asthma management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14486334\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Suzanne Fletcher, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/2\">",
"      Fahy JV, O'Byrne PM. \"Reactive airways disease\". A lazy term of uncertain meaning that should be abandoned. Am J Respir Crit Care Med 2001; 163:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/3\">",
"      Yunginger JW, Reed CE, O'Connell EJ, et al. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis 1992; 146:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/4\">",
"      Pratter MR, Hingston DM, Irwin RS. Diagnosis of bronchial asthma by clinical evaluation. An unreliable method. Chest 1983; 84:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/5\">",
"      Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/6\">",
"      Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med 1989; 149:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/7\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/8\">",
"      Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.org (Accessed onSeptember 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/10\">",
"      Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests. Asthma outcome. Am J Respir Crit Care Med 1994; 149:S9.",
"     </a>",
"    </li>",
"    <li>",
"     Irvin, CG, Eidelman, D. Airways mechanics in asthma. In: Rhinitis and Asthma, Holgate, S, Busse, W (Eds), Blackwell Scientific Publications, Boston 1995.",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. International consensus report on diagnosis and treatment of asthma. U.S. Government Printing Office, Washington D.C. PHHS Publication No. 92-3091, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/13\">",
"      Smith HR, Irvin CG, Cherniack RM. The utility of spirometry in the diagnosis of reversible airways obstruction. Chest 1992; 101:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/14\">",
"      Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008; 179:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/15\">",
"      Aguilar-Fern&aacute;ndez AJ, Villa-Asensi JR, Castro-Codesal M, et al. Concordance between the Piko - 1 portable device and pneumotachography in measuring PEF and FEV(1) in asthmatic children. Allergol Immunopathol (Madr) 2009; 37:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/16\">",
"      Solomon DA, Fanta CH, Levy BD, Loscalzo J. Clinical problem-solving. Whistling in the dark. N Engl J Med 2012; 366:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/17\">",
"      Scott S, Currie J, Albert P, et al. Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. Chest 2012; 141:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/18\">",
"      Gaugris S, Sazonov-Kocevar V, Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J Asthma 2006; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/1/19482/abstract/19\">",
"      Meltzer EO. The relationships of rhinitis and asthma. Allergy Asthma Proc 2005; 26:336.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 543 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19482=[""].join("\n");
var outline_f19_1_19482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24992570\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bronchodilator response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2957546\">",
"      - Peak expiratory flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Exhaled nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tests for allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24992678\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Initial spirometry shows airflow limitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Initial spirometry is normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Serial measurements of lung function over time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bronchoprovocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis based on history and clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20489068\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20489413\">",
"      Conditions causing similar symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20489160\">",
"      Conditions producing obstructive patterns on spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20489168\">",
"      Co-existent conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14486334\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/543|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/4/26688\" title=\"figure 1\">",
"      Nasal polyps in nostril",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/26/16814\" title=\"figure 2\">",
"      Severity obstructive dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/47/36605\" title=\"figure 3\">",
"      Obstructive flow volume curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 4\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/43005\" title=\"figure 5\">",
"      Bronchoprovocation test asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/21/14686\" title=\"figure 6\">",
"      Diary record of PEFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/40/28302\" title=\"figure 7\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/31/24051\" title=\"picture 1\">",
"      Adult atopic dermatitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/10/42147\" title=\"picture 2\">",
"      Adult atopic dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35357\" title=\"table 1\">",
"      Asthma trigger questions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/7/22653\" title=\"table 2\">",
"      Asthma severity 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/51/22331\" title=\"table 3\">",
"      Performance of PEF maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/12/36044\" title=\"table 4A\">",
"      PEFR in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/17/36124\" title=\"table 4B\">",
"      PEFR in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/12/1229\" title=\"table 5\">",
"      PEFR in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10139\" title=\"table 6\">",
"      Constrictive bronchiolitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/9/14481?source=related_link\" title=\"calculator 1\">",
"      Calculator: Peak Expiratory Flow Prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=related_link\">",
"      Diagnosis and management of asthma in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=related_link\">",
"      Diagnosis of wheezing illnesses other than asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=related_link\">",
"      Genetics of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_1_19483="Risk factors for dengue HF";
var content_f19_1_19483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors that influence the risk for dengue hemorrhagic fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        High risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Viral",
"factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral",
"serotype",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Dengue-2",
"virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral",
"genotype",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        \"Asian\"",
"genotypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Host",
"factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Prior dengue virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age",
"       </td>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nutrition",
"       </td>",
"       <td>",
"        Malnourished",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genetics",
"       </td>",
"       <td>",
"        Black",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19483=[""].join("\n");
var outline_f19_1_19483=null;
var title_f19_1_19484="ART for occupational PEP against HIV";
var content_f19_1_19484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral regimens for occupational postexposure prophylaxis of HIV infection*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preferred regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine 300/200 mg coformulation once daily",
"        <strong>",
"         plus",
"        </strong>",
"        raltegravir 400 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternative regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine 300/200 mg coformulation once daily",
"        <strong>",
"         plus",
"        </strong>",
"        atazanavir 300 mg once daily&nbsp;with ritonanvir 100 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine 300/200 mg coformulation once daily",
"        <strong>",
"         plus",
"        </strong>",
"        darunavir 800 mg once daily with ritonanvir 100 mg once daily taken&nbsp;with food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional possible regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine 300/200 mg coformulation once daily",
"        <strong>",
"         plus",
"        </strong>",
"        lopinavir-ritonavir 400/100 mg coformulation twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Efavirenz",
"        <sup>",
"         &bull;",
"        </sup>",
"        -tenofovir-emtricitabine 600/300/200 mg coformulation once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stavudine 30 mg twice daily&nbsp;",
"        <strong>",
"         plus",
"        </strong>",
"        either lamivudine 150 mg twice daily or emtricitabine 200 mg once daily,&nbsp;in place of tenfovir-emtricitabine in one of the above regimens, if tenofovir&nbsp;should be&nbsp;avoided (eg in setting of renal insufficiency)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These are recommendations of the authors and are consistent with the 2012 United States Department of Health and Human Services guidelines for treatment of HIV-infected adults.",
"    <div class=\"footnotes\">",
"     * Usual duration of post-exposure prophylaxis (PEP) is 28 days.&nbsp;Doses shown are for adults with normal renal function.&nbsp;Dose adjustment for renal insufficiency may be needed.",
"     <br>",
"      &bull; Efavirenz is preferably avoided in women of child-bearing potential.&nbsp;Cognitive side effects due to efavirenz may be better tolerated by taking the coformulation at bedtime.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 1-239. Available at&nbsp;&nbsp;",
"     <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\">",
"      file://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf",
"     </a>",
"     &nbsp; Accessed&nbsp;27&nbsp;November 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19484=[""].join("\n");
var outline_f19_1_19484=null;
var title_f19_1_19485="Laboratory findings - Brucellosis";
var content_f19_1_19485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings - Brucellosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"10\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Literature reference",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"9\">",
"        Percent of patients with the given feature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        ESR",
"        <br/>",
"        &gt;20 mm/h",
"       </td>",
"       <td class=\"subtitle2\">",
"        CRP",
"        <br/>",
"        &gt;5 mg/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        ALT",
"        <br/>",
"        &gt;40 U/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Leucopenia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Leucocytosis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lymphocytes",
"        <br/>",
"        &gt;45 percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Thrombocytopenia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Anemia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pancytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pappas, et al. 2005",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dokuzoguz, et al. 2005",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aygen, et al. 2002",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yinnon, et al. 1993",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pourbagher, et al. 2006",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gur, et al. 2003",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hizel, et al. 2007",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colmenero, et al. 1990",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bosilkovski, et al. 2010",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Frequency of hematological and biochemical features in patients with brucellosis, as reported in the literature and in the CMJ study.",
"    <div class=\"footnotes\">",
"     ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: alanine aminotransferase; ND: not determined.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bosilkovski M, Krteva L, Dimova M, et al. Human Brucellosis in Macedonia &ndash; 10 years of Clinical Experience in Endemic Region. Croat Med J 2010; 51:327. Copyright &copy; 2010 Croatian Medical Journal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19485=[""].join("\n");
var outline_f19_1_19485=null;
var title_f19_1_19486="Electrical fields";
var content_f19_1_19486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrical dipole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 160px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A dipole is created when one part of the muscle strip becomes electrically negative relative to the rest of the muscle strip. Movement of the dipole from negative to positive (arrow) creates an electrical field.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19486=[""].join("\n");
var outline_f19_1_19486=null;
var title_f19_1_19487="Physiologic progression of the thigh-foot angle";
var content_f19_1_19487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Physiologic progression of the thigh-foot angle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean (line) and normal range (two standard deviations) of the thigh-foot angle according to age (years).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Staheli LT. Lower limb. In: Fundamentals of Pediatric Orthopedics, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_1_19487=[""].join("\n");
var outline_f19_1_19487=null;
